hydroxychloroquine has been researched along with Retinal Diseases in 413 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Retinal Diseases: Diseases involving the RETINA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the potential ocular toxicity of a combined BRAF inhibition (BRAFi) + MEK inhibition (MEKi) + hydroxychloroquine (HCQ) regime used to treat metastatic BRAF mutant melanoma." | 9.30 | FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. ( Aleman, TS; Amaravadi, RK; Bowman, S; Edelstein, ID; Gangadhar, TC; Huang, A; Kim, BJ; Mitnick, S; Nichols, CW; Nti, AA; Sandhu, HS; Schuchter, LM; Serrano, LW; Song, D; Uyhazi, KE; Zhou, EJ, 2019) |
| "Rheumatoid arthritis (RA) is the most common inflammatory joint disease, and hydroxychloroquine (HCQ) is an established treatment." | 8.31 | Retinal microvascular density analysis in patients with rheumatoid arthritis treated with hydroxychloroquine. ( Esser, EL; Eter, N; Mihailovic, N; Storp, JJ; Zimmermann, JA, 2023) |
| "The aim of this study is to measure retinal vessel density and thickness of the macula by optical coherence tomography angiography in patients with rheumatoid arthritis taking hydroxychloroquine." | 7.91 | The optical coherence tomography angiography findings of rheumatoid arthritis patients taking hydroxychloroquine. ( Coskun, C; Karaca, EE; Kemer, OE; Omma, A; Onen, M; Ozek, D, 2019) |
| "To study whether the ERG and other clinical findings help to distinguish between advanced hydroxychloroquine (HCQ) retinopathy and pericentral or diffuse retinitis pigmentosa (RP) with similar fundus appearance." | 7.85 | ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa. ( Marmor, MF; Nair, AA, 2017) |
| "Hydroxychloroquine (HCQ) retinopathy can accompany other retinal complications such as cystoid macular edema (CME), which leads to central visual loss." | 7.85 | The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report. ( Ahn, SJ; Hong, EH; Lee, BR; Lim, HW, 2017) |
| "To compare the retinal toxicity due to hydroxychloroquine (HCQ) use in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) using multifocal electroretinography (mfERG), fundus autofluorescence (FAF) and optical coherence tomography (OCT)." | 7.85 | Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis. ( Ornek, F; Ozdemir, Y; Sungur, G; Telek, HH; Yesil, NK; Yesilirmak, N, 2017) |
| "To describe a series of patients with Stargardt disease (STGD1) exhibiting a phenotype usually associated with hydroxychloroquine (HCQ) retinopathy on spectral domain-optical coherence tomography (SD-OCT)." | 7.83 | Recessive Stargardt disease phenocopying hydroxychloroquine retinopathy. ( Allikmets, R; Greenstein, VC; Lee, W; Nõupuu, K; Tsang, S; Zernant, J, 2016) |
| "Hydroxychloroquine (HCQ) is an antimalarial drug used extensively in treatment of autoimmune diseases such as rheumatoid arthritis." | 7.81 | Detection of Hydroxychloroquine Retinal Toxicity by Automated Perimetry in 60 Rheumatoid Arthritis Patients with Normal Fundoscopic Findings. ( Abbaszadeh, M; Aidenloo, NS; Motarjemizadeh, Q, 2015) |
| "To evaluate retinal toxicity in patients treated with high-dose hydroxychloroquine (HCQ) (Plaquenil, Sanofi Pharmaceuticals) for chronic graft-versus-host disease (GVHD)." | 7.81 | Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. ( Boyd, S; Easterbrook, M; Hammoudi, DS; Krema, H; Lipton, JH; Navajas, EV; Simpson, ER, 2015) |
| "Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e." | 5.72 | Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report. ( Ameen Ismail, A; Hatata, RM; Sadek, SH, 2022) |
| "To assess the potential ocular toxicity of a combined BRAF inhibition (BRAFi) + MEK inhibition (MEKi) + hydroxychloroquine (HCQ) regime used to treat metastatic BRAF mutant melanoma." | 5.30 | FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial. ( Aleman, TS; Amaravadi, RK; Bowman, S; Edelstein, ID; Gangadhar, TC; Huang, A; Kim, BJ; Mitnick, S; Nichols, CW; Nti, AA; Sandhu, HS; Schuchter, LM; Serrano, LW; Song, D; Uyhazi, KE; Zhou, EJ, 2019) |
| "To check the ability of microperimetry to detect early retinal damage in patients with rheumatism taking hydroxychloroquine (HCQ), chloroquine (CQ), or both, and to describe the microperimetric alterations attributable to these drugs and their correlation with some clinical variables." | 5.17 | Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity. ( Beltrán-Catalán, E; Epifanio, I; Marco-Ventura, P; Martínez-Costa, L; Murcia-Bello, C; Verdejo-Gimeno, C; Victoria Ibañez, M, 2013) |
| "Hydroxychloroquine (HCQ) is used in the treatment of rheumatologic diseases including systemic lupus erythematosus, rheumatoid arthritis and other conditions." | 5.05 | [Hydroxychloroquine treatment rarely causes eye damage when used correctly]. ( Andersen, J; Bay-Laurberg, T; Clemmensen, K; Deleuran, B; Troldborg, A, 2020) |
| "Despite advances in therapy for rheumatic diseases, hydroxychloroquine remains almost universally recommended for the treatment of systemic lupus erythematosus (SLE), and is often used in the management of other rheumatic diseases such as rheumatoid arthritis (RA)." | 4.98 | Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. ( Choi, HK; Jorge, A; Melles, RB; Ung, C; Young, LH, 2018) |
| "Chloroquine (CQ) and hydroxycholorquine (HCQ) have been used widely for the treatment of rheumatoid arthritis and other similar inflammatory diseases since the early 50s." | 4.82 | Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. ( Tzekov, R, 2005) |
| "In the United States, hydroxychloroquine (Plaquenil) is one of the most commonly prescribed medications for mild to moderately severe rheumatoid arthritis." | 4.78 | Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity. ( Aylward, JM, 1993) |
| "To report a rare case of cystoid macular edema (CME) as a presentation of acute hydroxychloroquine-related retinal toxicity." | 4.31 | Unusual Presentation of Acute Hydroxychloroquine Retinopathy. ( Cheng, CK; Lian, YY; Ma, YC, 2023) |
| "Rheumatoid arthritis (RA) is the most common inflammatory joint disease, and hydroxychloroquine (HCQ) is an established treatment." | 4.31 | Retinal microvascular density analysis in patients with rheumatoid arthritis treated with hydroxychloroquine. ( Esser, EL; Eter, N; Mihailovic, N; Storp, JJ; Zimmermann, JA, 2023) |
| "Hydroxychloroquine is an effective treatment for rheumatic diseases; however, retinal damage is a possible side effect." | 4.31 | Cone Density Distribution and Related Factors in Patients Receiving Hydroxychloroquine Treatment. ( Huang, H; Liu, H; Liu, X; Mo, S; Tang, J; Zhu, Z, 2023) |
| "Hydroxychloroquine (HCQ) is an important medication for patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases." | 4.12 | RetINal Toxicity And HydroxyChloroquine Therapy (INTACT): protocol for a prospective population-based cohort study. ( Adante, B; Aviña-Zubieta, JA; Bhui, RD; Bhui, SB; Butler, M; Chui, L; Daftarian, N; Dawes, M; Erasmus, M; Esdaile, J; Etminan, M; Godinho, D; Hay, E; Hoens, A; Hollands, H; Hoonjan, M; Joe, A; Levasseur, SD; Lima, A; Lukaris, A; Maberley, DAL; Mammo, Z; Marozoff, S; Navajas, E; Ojo, D; Pakzad-Vaezi, K; Sanmugasunderam, S; Shojania, K, 2022) |
| "A 62-year-old white woman with erosive rheumatoid arthritis developed hydroxychloroquine toxicity in her phakic eye, with her aphakic fellow eye only mildly affected." | 4.02 | ASYMMETRIC HYDROXYCHLOROQUINE MACULAR TOXICITY WITH APHAKIC FELLOW EYE. ( Fuzzard, DRW; Heriot, WJ; Mack, HG; Symons, RCA, 2021) |
| " The prolonged use of chloroquine and hydroxychloroquine can cause hyperpigmentation in the skin, oral mucosa and retinal pigment epithelium, which in turn can trigger toxicity in this epithelium, which in some cases causes vision loss." | 3.96 | Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus. ( Chacón-Dulcey, V; Frías, J; González, N; López-Labady, J; Pérez Alfonzo, R; Tirado, W; Villarroel-Dorrego, M, 2020) |
| "The increasing prevalence of obesity over the past 60 years implies the need to reassess the risk of hydroxychloroquine retinopathy (HR) in obese women using the American Academy of Ophthalmology (AAO) 2016 guidelines." | 3.91 | The 2016 American Academy of Ophthalmology Hydroxychloroquine Dosing Guidelines For Short, Obese Patients. ( Browning, DJ; Easterbrook, M; Lee, C, 2019) |
| "The aim of this study is to measure retinal vessel density and thickness of the macula by optical coherence tomography angiography in patients with rheumatoid arthritis taking hydroxychloroquine." | 3.91 | The optical coherence tomography angiography findings of rheumatoid arthritis patients taking hydroxychloroquine. ( Coskun, C; Karaca, EE; Kemer, OE; Omma, A; Onen, M; Ozek, D, 2019) |
| "To assess the sensitivity and specificity of microperimetry as a screening test to detecting hydroxychloroquine retinopathy." | 3.91 | MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study. ( Iftikhar, M; Kaur, R; Kherani, S; Nefalar, A; Petri, M; Rashid, I; Scholl, HPN; Schönbach, E; Shah, SM; Usmani, B, 2019) |
| "Patients who used hydroxychloroquine continuously for at least 2 years for various connective tissue diseases were included in the study." | 3.91 | Evaluation of Maculopathy in Patients Using Hydroxychloroquine ( Aslanova, M; Cebeci, Z; Kır Mercül, N; Uğurlu, A, 2019) |
| "A 61-year-old woman with rheumatoid arthritis treated with 400 mg/kg hydroxychloroquine daily for 6 years (daily dose, 5." | 3.88 | Case Report: Hydroxychloroquine Retinopathy. ( Chan, EW; Eldeeb, M; Omar, A, 2018) |
| "Hydroxychloroquine (HCQ) retinopathy may be more common than previously recognized; recent ophthalmology guidelines have revised recommendations from ideal body weight (IBW)-based dosing to actual body weight (ABW)-based dosing." | 3.88 | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. ( Aranow, C; Askanase, A; Choi, H; Clarke, AE; Costenbader, KH; Esdaile, JM; Jorge, AM; Lim, SS; Lu, N; Melles, RB; Petri, M; Rai, SK; Ramsey-Goldman, R; Urowitz, MB; Young, LH; Zhang, Y, 2018) |
| "To study whether the ERG and other clinical findings help to distinguish between advanced hydroxychloroquine (HCQ) retinopathy and pericentral or diffuse retinitis pigmentosa (RP) with similar fundus appearance." | 3.85 | ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa. ( Marmor, MF; Nair, AA, 2017) |
| "Hydroxychloroquine (HCQ) retinopathy can accompany other retinal complications such as cystoid macular edema (CME), which leads to central visual loss." | 3.85 | The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report. ( Ahn, SJ; Hong, EH; Lee, BR; Lim, HW, 2017) |
| "To compare the retinal toxicity due to hydroxychloroquine (HCQ) use in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) using multifocal electroretinography (mfERG), fundus autofluorescence (FAF) and optical coherence tomography (OCT)." | 3.85 | Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis. ( Ornek, F; Ozdemir, Y; Sungur, G; Telek, HH; Yesil, NK; Yesilirmak, N, 2017) |
| "To describe a series of patients with Stargardt disease (STGD1) exhibiting a phenotype usually associated with hydroxychloroquine (HCQ) retinopathy on spectral domain-optical coherence tomography (SD-OCT)." | 3.83 | Recessive Stargardt disease phenocopying hydroxychloroquine retinopathy. ( Allikmets, R; Greenstein, VC; Lee, W; Nõupuu, K; Tsang, S; Zernant, J, 2016) |
| "Optical coherence tomography retinal thickness and 10-2 VFMD are objective measures demonstrating clinically useful sensitivity and specificity for the detection of hydroxychloroquine toxicity as identified by mfERG, and thus may be suitable surrogate tests." | 3.81 | Subjective and objective screening tests for hydroxychloroquine toxicity. ( Cukras, C; Ferris, FL; Huynh, N; Sieving, PA; Vitale, S; Wong, WT, 2015) |
| "Hydroxychloroquine (HCQ) is an antimalarial drug used extensively in treatment of autoimmune diseases such as rheumatoid arthritis." | 3.81 | Detection of Hydroxychloroquine Retinal Toxicity by Automated Perimetry in 60 Rheumatoid Arthritis Patients with Normal Fundoscopic Findings. ( Abbaszadeh, M; Aidenloo, NS; Motarjemizadeh, Q, 2015) |
| "To evaluate retinal toxicity in patients treated with high-dose hydroxychloroquine (HCQ) (Plaquenil, Sanofi Pharmaceuticals) for chronic graft-versus-host disease (GVHD)." | 3.81 | Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. ( Boyd, S; Easterbrook, M; Hammoudi, DS; Krema, H; Lipton, JH; Navajas, EV; Simpson, ER, 2015) |
| "To determine whether patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) taking chloroquine or hydroxychloroquine are regularly visiting eye care providers and being screened for maculopathy." | 3.80 | Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. ( Blachley, TS; Edwards, P; Lee, PP; Nika, M; Stein, JD, 2014) |
| "To define the risk of hydroxychloroquine (HCQ)-related retinal toxicity in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) who are receiving recommended dosages of the drug (< or =6." | 3.72 | The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. ( Kostopoulos, C; Mavrikakis, E; Mavrikakis, I; Mavrikakis, M; Nikolaou, A; Rougas, K; Sfikakis, PP, 2003) |
| "Multifocal ERG with 103-hexagon stimulation was performed on 19 patients (36 eyes) treated with hydroxychloroquine for systemic lupus erythematosus, rheumatoid arthritis, or localized atypical scleroderma." | 3.72 | Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. ( Maturi, RK; Weleber, RG; Yu, M, 2004) |
| "All the patients (73) in the Rheumatology Department five year study of second line therapy who have taken hydroxychloroquine (Plaquenil) for rheumatoid arthritis for longer than 18 months were reviewed." | 3.68 | Screening for hydroxychloroquine retinal toxicity: is it necessary? ( Jessop, JD; Livesey, SJ; Mills, PV; Morsman, CD; Richards, IM, 1990) |
| "C-wave and ERG records have been taken from patients with juvenile macular degeneration, cone dysfunction syndrome, non exudative macular degeneration and from patients who have taken hydroxychloroquine for more than a year." | 3.67 | [C-wave changes in macular diseases]. ( Brouza, D; Moschos, M; Panagakis, E, 1989) |
| " Typically, the doses were 2 to 5 times greater than the AAO recommendation (adjusted to weight) to avoid toxic retinopathy, the most undesirable ocular side effect." | 2.72 | What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. ( Altemir-Gómez, I; Fambuena-Muedra, I; Hershko, S; Jiménez-García, M; Tobarra-López, A, 2021) |
| "Hydroxychloroquine is an age-old drug whose use as an immunomodulatory agent with a low side-effect profile continues to expand." | 2.66 | Hydroxychloroquine in dermatology: New perspectives on an old drug. ( Chew, CY; Mar, A; Nikpour, M; Saracino, AM, 2020) |
| "To describe the rationale for revising the hydroxychloroquine (HCQ) dosing and screening guidelines and to identify the barriers to more effective guidelines in the future." | 2.66 | Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines. ( Browning, DJ; Greenberg, PB; Perlman, E; Yokogawa, N, 2020) |
| "Effective treatment of retinal diseases with adeno-associated virus (AAV)-mediated gene therapy is highly dependent on the proportion of successfully transduced cells." | 2.66 | Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy. ( Barnard, AR; Chandler, LC; MacLaren, RE; McClements, ME; Xue, K; Yusuf, IH, 2020) |
| "Antimalarial drugs including chloroquine, its less toxic quinolone-derivative hydroxychloroquine (HCQ), and quinacrine have become cornerstones in the treatment of autoimmune diseases including systemic lupus, rheumatoid arthritis, sarcoidosis, and Sjogren syndrome; cutaneous disorders, antiphospholipid syndrome, and have recently been employed at higher dioses in oncology." | 2.58 | Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. ( Abdulaziz, N; McCune, WJ; Shah, AR, 2018) |
| "Hydroxychloroquine is an immunomodulatory drug that has been used for 60 years to treat malaria and autoimmune diseases such as systemic lupus erythematosus and inflammatory arthritis, and potential new uses and benefits continue to emerge." | 2.58 | Hydroxychloroquine: An old drug with new relevance. ( Collamer, AN; Shippey, EA; Wagler, VD, 2018) |
| "Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functions by increasing the pH." | 2.55 | Hydroxychloroquine in systemic lupus erythematosus (SLE). ( Moroni, G; Ponticelli, C, 2017) |
| "Hydroxychloroquine has demonstrated a survival benefit in patients with systemic lupus erythematosus; some clinicians advocate its use in all such patients." | 2.55 | Hydroxychloroquine retinopathy. ( Downes, SM; Luqmani, R; Sharma, S; Yusuf, IH, 2017) |
| "HCQ is widely used for the treatment of rheumatic diseases, particularly lupus and RA." | 2.53 | Hydroxychloroquine-related retinal toxicity. ( Denniston, AK; Ding, HJ; Gordon, C; Rao, VK, 2016) |
| " For this reason, the key question is weather these drugs are absolutely safe and can be long term used in all lupus patients as a background therapy? Potential non-specific side effects occur very rare and are usually minor and last for short period." | 2.53 | [Current view on chloroquine derivative treatment from rheumatologist perspective and possible ocular side effects]. ( Gaca-Wysocka, M; Grzybowski, A; Leszczyński, P; Pawlak-Buś, K, 2016) |
| " A higher dosage per kg body mass, long therapy duration, presence of keratopathy and renal or hepatic dysfunction are probably associated with an increased risk to develop a maculopathy/retinopathy." | 2.45 | [Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up]. ( Pluta, JP; Rüther, K, 2009) |
| " Although its pathogenesis is unclear, risk factors include: daily dosage of hydroxychloroquine, cumulative dosage, duration of treatment, coexisting renal or liver disease, patient age, and concomitant retinal disease." | 2.43 | Ocular toxicity of hydroxychloroquine. ( Kwok, AK; Yam, JC, 2006) |
| " Patients should be dosed on the basis of ideal body weight (not actual body weight) to reduce the incidence of macular toxicity." | 2.40 | Detection and prevention of maculopathy associated with antimalarial agents. ( Easterbrook, M, 1999) |
| " The dosage parameters associated with retinopathy are still uncertain as well as the best way to screen for it but the dosage/kg body weight appears to be important." | 2.39 | Retinopathy and antimalarial drugs--the British experience. ( Spalton, DJ, 1996) |
| " Small risk factors may appear at this dosage level only when the duration of treatment exceeds ten years and/or chronic renal insufficiency is present." | 2.38 | Ocular safety of hydroxychloroquine. ( Bernstein, HN, 1991) |
| " Retinopathy can be avoided by observing a maximum daily dosage of 3." | 2.38 | [Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs]. ( Ochsendorf, FR; Runne, U, 1991) |
| " Many of these reviews, while generally excellent, have propagated some apparent misconceptions by disregarding or de-emphasizing data suggesting that irreversible retinal toxicity due to antimalarials can be easily avoided by judicious daily dosage and regular ophthalmologic follow-up." | 2.36 | Antimalarials and ophthalmologic safety. ( Olansky, AJ, 1982) |
| "Patients with low oral HCQ dosage tend to have more flares, although the difference was not statistically significant." | 1.91 | Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus. ( Ciccia, F; Coscia, MA; Fasano, S; Iudici, M; Messiniti, V, 2023) |
| "Hydroxychloroquine dose was assessed from pharmacy dispensing records." | 1.91 | Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study. ( Choi, HK; Conell, C; Jorge, AM; Marmor, MF; McCormick, N; Melles, RB; Niu, J; Zhang, Y; Zhou, B, 2023) |
| " Study results indicated that HCQ dosing management was adequate based on the revised guidelines." | 1.91 | Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus. ( Jung, SY; Kim, YJ; Lee, JE; Nam, DR; Sung, YK, 2023) |
| "Hydroxychloroquine (HCQ) is an anti-malarial drug but also widely used to treat autoimmune diseases like arthritis and lupus." | 1.72 | Hydroxychloroquine Causes Early Inner Retinal Toxicity and Affects Autophagosome-Lysosomal Pathway and Sphingolipid Metabolism in the Retina. ( Basu, SK; Chalfant, CE; Chiu, CY; Cole, J; Khanam, S; Mandal, N; Mondal, K; Pandya, HK; Porter, H; Shah, V; Stephenson, DJ, 2022) |
| "Hydroxychloroquine (HCQ) is an anti-inflammatory drug in widespread use for the treatment of systemic auto-immune diseases." | 1.72 | MERCI: a machine learning approach to identifying hydroxychloroquine retinopathy using mfERG. ( Gupta, A; Habib, F; Huang, H; Wright, T, 2022) |
| "Hydroxychloroquine is a widely used medication for various clinical conditions mainly rheumatological and dermatological autoimmune diseases e." | 1.72 | Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report. ( Ameen Ismail, A; Hatata, RM; Sadek, SH, 2022) |
| "Ocular manifestations in systemic lupus erythematosus (SLE) can be the presenting symptom of the disease or a sight-threatening complication." | 1.62 | Structural Retinal Assessment Using Optical Coherence Tomography and Fundus Fluorescein Angiography in Systemic Lupus Erythematosus Patients. ( El-Gendy, H; Esmat Mahmoud Ali, SM; Essam, M; Fouad, SA; Mahfouz, S; Rezk Alnaggar, ARL, 2021) |
| "Hydroxychloroquine (HCQ) maculopathy is irreversible; primary prevention is done by regular monitoring." | 1.62 | An objective method of diagnosing hydroxychloroquine maculopathy. ( Hasan, H; Lotery, A; Price, EJ; Smith, GT, 2021) |
| " At a daily dosage of ≤5 mg/kg/day actual body weight, the risk of retinal toxicity from HCQ is <2% for usage up to 10 years." | 1.62 | American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. ( Costenbader, KH; Desmarais, J; Fett, N; Ginzler, EM; Goodman, SM; Marmor, MF; Melles, RB; O'Dell, JR; Rosenbaum, JT; Schmajuk, G; Werth, VP, 2021) |
| "Hydroxychloroquine retinopathy was prevalent in the study cohort and significantly associated with a higher daily dose of HCQ (mg/kg real body weight)." | 1.62 | Prevalence of hydroxychloroquine retinopathy with long-term use in a cohort of Indian patients with rheumatic diseases. ( Bafna, P; Hazarika, K; Kaur, A; Manoj, M; Sahoo, RR; Singh, A; Wakhlu, A, 2021) |
| " Advances in our understanding of HCQ retinopathy have led to changes in the recommendations for HCQ dosing and retinopathy screening." | 1.62 | Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence. ( Andersen, J; Bultink, IEM; Cornet, A; Frankel, S; Osmani, Z; Schrama, TJ; van Vollenhoven, RF; Zacouris-Verweij, W, 2021) |
| "Hydroxychloroquine has excellent anti-inflammatory and immunomodulatory effects as one of the antimalarial drugs." | 1.62 | Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report. ( Li, J; Liao, Z; Qi, W; Tian, F; Wang, G; Wen, Z; Zhuo, N, 2021) |
| "Hydroxychloroquine (HCQ) has become the rheumatologists's "Swiss army knife" when it comes to managing the rheumatologic manifestations of SLE and other auto-immune disorders." | 1.56 | What every nephrologist needs to know about hydroxychloroquine toxicity . ( Ardoin, S; Ayoub, I; Brodsky, S; Hebert, L; Singh, P, 2020) |
| "All patients with HCQ toxicity showed significantly prolonged FLIO lifetimes in regions of damage, typically in a bulls-eye distribution corresponding to toxic lesions in the retina (SSC: lesion, 400 ps; unremarkable retina, 294 ps; P < 0." | 1.51 | Imaging of Hydroxychloroquine Toxicity with Fluorescence Lifetime Imaging Ophthalmoscopy. ( Bernstein, PS; Calvo, CM; Henrie, N; Milliken, CM; Sauer, L; Vitale, AS, 2019) |
| "We aimed to assess the impact of ophthalmology weight-based hydroxychloroquine (HCQ) dosing guidelines on prescribing patterns." | 1.48 | Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016. ( Choi, HK; Jorge, AM; Marmor, MF; Melles, RB; Zhang, Y, 2018) |
| "Retinal involvement in systemic lupus erythematosus (SLE) and Sjögren syndrome (SS) may be subclinical and thus underdiagnosed." | 1.48 | Evidence for the Detection of Subclinical Retinal Involvement in Systemic Lupus Erythematosus and Sjögren Syndrome: A Potential Association with Therapies. ( Aloe, G; Canofari, C; Cesareo, M; Chimenti, MS; Conigliaro, P; Draghessi, G; Nucci, C; Perricone, R; Triggianese, P; Valeri, C, 2018) |
| "9 years and daily dosage ranging from 4." | 1.46 | Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine. ( Choe, JY; Kim, JW; Kim, SK; Kim, YY; Lee, H; Park, SH, 2017) |
| "We included 124 patients with systemic lupus erythematosus or rheumatoid arthritis who were treated with HCQ." | 1.46 | Choroidal Thinning Associated With Hydroxychloroquine Retinopathy. ( Ahn, SJ; Joung, JY; Lee, BR; Ryu, SJ, 2017) |
| "To study the adherence of rheumatologists to the hydroxychloroquine (HCQ) dosing guidelines established by the American Academy of Ophthalmology in 2011 and 2016." | 1.46 | Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System. ( Braslow, RA; Macsai, MS; Shiloach, M, 2017) |
| " However, long-term use can be associated with irreversible retinal toxicity." | 1.46 | Hydroxychloroquine retinopathy: an emerging problem. ( Downes, SM; Gourier, H; Latasiewicz, M; Luqmani, R; Sharma, SM; Yusuf, IH, 2017) |
| "Forty-two patients with systemic lupus erythematosus underwent ocular examination based on visual acuity evaluation, optical coherence tomography retinal thickness measurements, and multifocal electroretinography (mfERG) records at first visit." | 1.42 | Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study. ( Chatziralli, IP; Gatzioufas, Z; Kitsos, G; Koutsandrea, C; Moschos, MM; Nitoda, E, 2015) |
| "To reassess the prevalence of and risk factors for hydroxychloroquine retinal toxicity and to determine dosage levels that facilitate safe use of the drug." | 1.40 | The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. ( Marmor, MF; Melles, RB, 2014) |
| "Red fields often showed more prominent scotomas in early retinopathy but sometimes showed irregular losses that were hard to evaluate." | 1.39 | Value of red targets and pattern deviation plots in visual field screening for hydroxychloroquine retinopathy. ( Chien, FY; Johnson, MW; Marmor, MF, 2013) |
| "Given the infrequent occurrence of hydroxychloroquine toxic effects, few data are available about the presenting features and long-term follow-up of patients with hydroxychloroquine retinopathy, making it difficult to surmise the clinical course of patients after cessation of drug treatment." | 1.39 | Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. ( Brenner, M; Bryar, PJ; Fawzi, AA; Jampol, LM; Mititelu, M; Wong, BJ, 2013) |
| "New hydroxychloroquine toxicity was found in 2 of 183 returning patients (1." | 1.39 | Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. ( Browning, DJ, 2013) |
| "To describe a case of hydroxychloroquine retinopathy combined with retinal pigment epithelium (RPE) detachment and evaluate possible causes of pigment epithelium detachment." | 1.38 | Hydroxychloroquine retinopathy combined with retinal pigment epithelium detachment. ( Ko, MK; Lee, BR; Lee, WJ, 2012) |
| " Careful screening with multiple tests can detect toxic damage before prominent loss of the outer nuclear layer." | 1.38 | Comparison of screening procedures in hydroxychloroquine toxicity. ( Marmor, MF, 2012) |
| " While every patient received 400 mg of hydroxychloroquine per day, every patient exceeded the recommended daily dosage allowance (6." | 1.37 | Clinical characteristics of hydroxychloroquine retinopathy. ( Aaberg, TM; Hubbard, GB; Payne, JF; Yan, J, 2011) |
| " In patients in whom the daily dosage of hydroxychloroquine could be estimated (12 of 13), when using actual body weight, 8 were taking 6." | 1.37 | Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. ( Francis, PJ; Michaelides, M; Stover, NB; Weleber, RG, 2011) |
| "The prior recommendation emphasized dosing by weight." | 1.37 | Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. ( Kellner, U; Lai, TY; Lyons, JS; Marmor, MF; Mieler, WF, 2011) |
| "In addition, she had a central scotoma (RE > LE) on automated visual field analysis (Humphrey central 30 degrees )." | 1.36 | Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up. ( Leroy, BP; Salu, P; Uvijls, A; van den Brande, P, 2010) |
| " Individual and weight-adapted dosing is especially essential for chloroquine." | 1.36 | Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. ( Bergholz, R; Rüther, K; Schroeter, J, 2010) |
| " Its use has been associated with ocular side effects; the most concerning is toxic maculopathy." | 1.35 | Retinal toxicity secondary to Plaquenil therapy. ( Hanna, B; Holdeman, NR; Schiffman, JS; Tang, RA, 2008) |
| " In at least one patient, the technique was able to detect the early onset of Plaquenil toxicity followed by reversal of the toxic effects after the medication was discontinued." | 1.35 | Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review : Review of mfERG ring ratios in Plaquenil toxicity. ( Lyons, JS; Severns, ML, 2009) |
| " A young patient presenting with toxic maculopathy after 57 g of hydroxychloroquine and a daily dosage of 2 mg/kg body weight prompted us to retrospectively look at our patients examined in this respect over about 1 year." | 1.34 | [Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses]. ( Berndt, S; Foerster, J; Rüther, K; Schroeter, J, 2007) |
| "Additionally, the average area of each scotoma detected by all three methods expanded from 34." | 1.33 | Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy. ( Almony, A; Garg, S; Kitridou, R; Mamet, R; Peters, RK; Sadun, AA; Shibuya, B; Tsong, J, 2005) |
| "Chloroquine treatment was discontinued." | 1.33 | [Severe chloroquine- and hydroxychloroquine-induced retinopathy]. ( Bui Quoc, E; Crochet, M; Dufier, JL; Ingster-Moati, I; Orssaud, C; Roche, O, 2006) |
| " Their clinical features illustrate that with normal renal function there is no threshold for total dosage for HCQ toxicity; that color vision testing is important; that almost all patients complain of altered central vision as their first symptom; and that a normal optic fundus does not exclude the diagnosis." | 1.31 | Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. ( Bienfang, D; Coblyn, JS; Corzillius, M; Liang, MH, 2000) |
| "All cases arose because of failure by physicians to avoid dosing above published safe levels." | 1.31 | Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. ( Browning, DJ, 2002) |
| "In HCQ-treated patients whose renal function is normal, routine ophthalmic screening is not indicated if the daily dosage is <6." | 1.30 | Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. ( Cohen, HB; Levy, GD; Munz, SJ; Paschal, J; Peterson, T; Pince, KJ, 1997) |
| "Hydroxychloroquine (HCQ) was used by 168 respondents, chloroquine (CQ) by 66, and mepacrine by 89 (only 111 always chose one of these)." | 1.29 | Ocular toxicity of antimalarials in dermatology: a survey of current practice. ( Cox, NH; Paterson, WD, 1994) |
| " The dosage recommended officially for this disease is vague." | 1.29 | Hydroxychloroquine. ( Potter, B, 1993) |
| " We believe special attention should be given to elderly patients who are being treated with hydroxychloroquine because their retinal pigment epithelium may be more susceptible to the toxic effects of this drug." | 1.29 | Hydroxychloroquine toxicity despite normal dose therapy. ( Falcone, PM; Lou, PL; Paolini, L, 1993) |
| "Both patients were treated for systemic lupus erythematosus; one patient was treated with 400 to 800 mg of hydroxychloroquine per day (6." | 1.28 | Hydroxychloroquine retinopathy. ( Berson, EL; Gaudio, AR; Kini, MM; Sandberg, MA; Weiner, A, 1991) |
| " Identical doses do not always produce the same effect and toxic symptoms have developed after a dosage ranging from 86 to 760 g." | 1.27 | [Routine monitoring of patients treated with synthetic antimalarials]. ( Bechetoille, A; Douche, C; Ebran, JM, 1983) |
| " I therefore consider these dosage rates safe, since they are below the threshold of retinal toxicity." | 1.27 | Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. ( Mackenzie, AH, 1983) |
| "Four cases of irreversible bilateral scotomas were detected in 8 eyes of 4 patients with normal static and kinetic fields in 7 of the 8 eyes." | 1.27 | The sensitivity of Amsler grid testing in early chloroquine retinopathy. ( Easterbrook, M, 1985) |
| " All patients received the medication for at least one year and most were treated with a daily dosage of 400 mg." | 1.26 | Hydroxychloroquine. Seven-year experience. ( Krohel, G; Rynes, RI; Tobin, DR, 1982) |
| "Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results." | 1.25 | Ocular manifestations of juvenile rheumatoid arthritis. ( Bellows, AR; Bienfang, DC; Chylack, LT; Stillman, JS, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (7.99) | 18.7374 |
| 1990's | 34 (8.23) | 18.2507 |
| 2000's | 48 (11.62) | 29.6817 |
| 2010's | 189 (45.76) | 24.3611 |
| 2020's | 109 (26.39) | 2.80 |
| Authors | Studies |
|---|---|
| Bitoun, S | 1 |
| Nocturne, G | 1 |
| Seror, R | 1 |
| Mariette, X | 1 |
| Bijan, S | 1 |
| Yu, SY | 1 |
| Kiri, G | 1 |
| Bhaleeya, S | 1 |
| Tzekov, R | 2 |
| Borrelli, E | 2 |
| Battista, M | 2 |
| Cascavilla, ML | 1 |
| Viganò, C | 1 |
| Borghesan, F | 1 |
| Nicolini, N | 1 |
| Clemente, L | 1 |
| Sacconi, R | 2 |
| Barresi, C | 1 |
| Marchese, A | 1 |
| Miserocchi, E | 2 |
| Modorati, G | 1 |
| Bandello, F | 1 |
| Querques, G | 3 |
| Fung, AT | 1 |
| Lu, V | 1 |
| Mack, HG | 3 |
| Tsang, A | 1 |
| Kanda, P | 1 |
| Gottlieb, C | 1 |
| Virgili, G | 3 |
| Kantungane, L | 1 |
| Coupland, S | 1 |
| Dabit, JY | 1 |
| Hocaoglu, M | 1 |
| Moder, KG | 1 |
| Barkmeier, AJ | 2 |
| Smith, WM | 1 |
| O'Byrne, TJ | 1 |
| Crowson, CS | 1 |
| Duarte-García, A | 1 |
| Jayakar, G | 1 |
| De Silva, T | 2 |
| Cukras, CA | 4 |
| Alveyn, E | 1 |
| Galloway, J | 5 |
| Daftarian, N | 1 |
| Lima, A | 1 |
| Marozoff, S | 1 |
| Ojo, D | 1 |
| Levasseur, SD | 1 |
| Maberley, DAL | 1 |
| Hoens, A | 1 |
| Esdaile, J | 1 |
| Dawes, M | 1 |
| Aviña-Zubieta, JA | 1 |
| Adante, B | 1 |
| Bhui, RD | 1 |
| Bhui, SB | 1 |
| Butler, M | 1 |
| Chui, L | 1 |
| Erasmus, M | 1 |
| Etminan, M | 1 |
| Godinho, D | 1 |
| Hay, E | 1 |
| Hollands, H | 1 |
| Hoonjan, M | 1 |
| Joe, A | 1 |
| Lukaris, A | 1 |
| Mammo, Z | 1 |
| Navajas, E | 1 |
| Pakzad-Vaezi, K | 1 |
| Sanmugasunderam, S | 1 |
| Shojania, K | 1 |
| Wright, T | 2 |
| Mason, R | 1 |
| Yan, P | 1 |
| Christakis, P | 1 |
| Easterbrook, M | 19 |
| Membreno, RF | 1 |
| Agrón, E | 1 |
| Keenan, TD | 1 |
| Mondal, K | 1 |
| Porter, H | 1 |
| Cole, J | 1 |
| Pandya, HK | 2 |
| Basu, SK | 1 |
| Khanam, S | 1 |
| Chiu, CY | 1 |
| Shah, V | 1 |
| Stephenson, DJ | 1 |
| Chalfant, CE | 1 |
| Mandal, N | 2 |
| Parrulli, S | 1 |
| Cozzi, M | 1 |
| Airaldi, M | 1 |
| Romano, F | 1 |
| Viola, F | 1 |
| Sarzi-Puttini, P | 1 |
| Staurenghi, G | 1 |
| Invernizzi, A | 1 |
| Arias-Peso, B | 1 |
| Méndez-Martínez, S | 1 |
| Pardiñas Barón, N | 1 |
| Habib, F | 1 |
| Huang, H | 2 |
| Gupta, A | 1 |
| Alieldin, RA | 1 |
| Boonarpha, N | 1 |
| Saedon, H | 1 |
| Lian, YY | 1 |
| Ma, YC | 1 |
| Cheng, CK | 1 |
| Kim, KE | 6 |
| Kim, JH | 2 |
| Kim, YH | 3 |
| Ahn, SJ | 16 |
| Kim, J | 2 |
| Ryu, SJ | 3 |
| Seo, Y | 1 |
| Arnon, R | 1 |
| Hilely, A | 1 |
| Halouani, S | 2 |
| Le, HM | 1 |
| Jung, C | 1 |
| Souied, EH | 2 |
| Miere, A | 1 |
| Ameen Ismail, A | 1 |
| Sadek, SH | 1 |
| Hatata, RM | 1 |
| Yusuf, IH | 12 |
| Han, RC | 3 |
| Downes, SM | 6 |
| Sharma, SM | 5 |
| Kellner, U | 7 |
| Kellner, S | 3 |
| Weinitz, S | 3 |
| Farmand, G | 3 |
| Almeida-Brasil, CC | 3 |
| Hanly, JG | 3 |
| Urowitz, M | 3 |
| Clarke, AE | 4 |
| Ruiz-Irastorza, G | 5 |
| Gordon, C | 4 |
| Ramsey-Goldman, R | 4 |
| Petri, MA | 3 |
| Ginzler, EM | 4 |
| Wallace, DJ | 3 |
| Bae, SC | 3 |
| Romero-Diaz, J | 3 |
| Dooley, MA | 3 |
| Peschken, C | 3 |
| Isenberg, D | 3 |
| Rahman, A | 3 |
| Manzi, S | 3 |
| Jacobsen, S | 3 |
| Lim, SS | 4 |
| van Vollenhoven, R | 3 |
| Nived, O | 3 |
| Jönsen, A | 3 |
| Kamen, DL | 3 |
| Aranow, C | 4 |
| Sánchez-Guerrero, J | 3 |
| Gladman, DD | 3 |
| Fortin, PR | 4 |
| Alarcon, GS | 4 |
| Merrill, JT | 3 |
| Kalunian, K | 3 |
| Ramos-Casals, M | 3 |
| Steinsson, K | 3 |
| Zoma, A | 3 |
| Askanase, AD | 3 |
| Khamashta, M | 3 |
| Bruce, IN | 3 |
| Inanc, M | 3 |
| Lukusa, L | 3 |
| Bernatsky, S | 4 |
| Tarassoly, K | 3 |
| Miraftabi, A | 3 |
| Sedaghat, A | 3 |
| Parvaresh, MM | 3 |
| Mauget-Faÿsse, M | 5 |
| Sukkarieh, G | 3 |
| Jebrane, H | 3 |
| Lafolie, J | 3 |
| Alonso, AS | 3 |
| Laumonier, E | 3 |
| Derrien, S | 3 |
| Le Guern, V | 5 |
| Behar Cohen, F | 3 |
| Thevenin, S | 3 |
| Auge, E | 3 |
| Guillaume, J | 3 |
| Vasseur, V | 4 |
| Costedoat-Chalumean, N | 3 |
| Esser, EL | 1 |
| Zimmermann, JA | 1 |
| Storp, JJ | 1 |
| Eter, N | 1 |
| Mihailovic, N | 1 |
| Guven, TK | 1 |
| Alexander, A | 1 |
| Smith, GT | 2 |
| Fasano, S | 1 |
| Messiniti, V | 1 |
| Iudici, M | 1 |
| Coscia, MA | 1 |
| Ciccia, F | 1 |
| Melles, RB | 12 |
| Jorge, AM | 3 |
| Marmor, MF | 35 |
| Zhou, B | 1 |
| Conell, C | 1 |
| Niu, J | 1 |
| McCormick, N | 1 |
| Zhang, Y | 3 |
| Choi, HK | 3 |
| Zone-Abid, I | 1 |
| Maaloul, K | 1 |
| Frikha, F | 1 |
| Marzouk, S | 1 |
| Bahloul, Z | 1 |
| Trigui, A | 1 |
| Mehta, P | 1 |
| Situ, BA | 1 |
| Wise, LM | 1 |
| Savvas, S | 1 |
| Daskivich, LP | 1 |
| Toy, BC | 1 |
| Lee, JE | 1 |
| Nam, DR | 1 |
| Sung, YK | 2 |
| Kim, YJ | 2 |
| Jung, SY | 1 |
| Tang, J | 1 |
| Liu, H | 1 |
| Mo, S | 1 |
| Zhu, Z | 1 |
| Liu, X | 1 |
| Browning, DJ | 10 |
| Lee, C | 1 |
| Joung, J | 4 |
| Lee, BR | 12 |
| Petri, M | 6 |
| Elkhalifa, M | 3 |
| Li, J | 5 |
| Magder, LS | 4 |
| Goldman, DW | 4 |
| Sharma, M | 1 |
| Kumar, M | 1 |
| Dutta, D | 1 |
| Chew, CY | 1 |
| Mar, A | 1 |
| Nikpour, M | 2 |
| Saracino, AM | 1 |
| Xie, WH | 1 |
| Zhang, ZL | 1 |
| Fouad, SA | 1 |
| Esmat Mahmoud Ali, SM | 1 |
| Rezk Alnaggar, ARL | 1 |
| Mahfouz, S | 1 |
| Essam, M | 1 |
| El-Gendy, H | 1 |
| Adamptey, B | 1 |
| Rudnisky, CJ | 1 |
| MacDonald, IM | 1 |
| Rabin, JC | 1 |
| Ramirez, K | 1 |
| Dahrouj, M | 1 |
| Young, L | 1 |
| Ayoub, I | 1 |
| Singh, P | 1 |
| Ardoin, S | 1 |
| Brodsky, S | 1 |
| Hebert, L | 1 |
| Dias-Santos, A | 1 |
| Tavares Ferreira, J | 1 |
| Pinheiro, S | 1 |
| Cunha, JP | 1 |
| Alves, M | 1 |
| Papoila, AL | 1 |
| Moraes-Fontes, MF | 2 |
| Proença, R | 1 |
| Yeo, B | 1 |
| Hamad, R | 1 |
| Paul, A | 1 |
| Low, A | 1 |
| Lotery, A | 2 |
| Burdon, M | 1 |
| Kaisari, E | 1 |
| Borruat, FX | 1 |
| de Sisternes, L | 3 |
| Pham, BH | 3 |
| Durbin, M | 2 |
| Carter, KL | 1 |
| Do, DV | 1 |
| Kowalski, T | 1 |
| Lucattini, A | 1 |
| Symons, RA | 1 |
| Wicks, I | 1 |
| Hall, AJ | 1 |
| Aduriz-Lorenzo, PM | 1 |
| Aduriz-Llaneza, P | 1 |
| Araiz-Iribarren, J | 1 |
| Khamashta, MA | 1 |
| Chacón-Dulcey, V | 1 |
| López-Labady, J | 1 |
| Villarroel-Dorrego, M | 1 |
| Frías, J | 1 |
| Tirado, W | 1 |
| González, N | 1 |
| Pérez Alfonzo, R | 1 |
| Romano, MR | 1 |
| Raimondi, R | 1 |
| Montericcio, A | 1 |
| Allegrini, D | 1 |
| Leroy, BP | 2 |
| Sivaprasad, S | 1 |
| Dollfus, H | 1 |
| Lenfant, T | 2 |
| Salah, S | 1 |
| Leroux, G | 3 |
| Bousquet, E | 1 |
| Chasset, F | 1 |
| Francès, C | 1 |
| Morel, N | 2 |
| Chezel, J | 1 |
| Papo, T | 1 |
| Cacoub, P | 1 |
| Mouthon, L | 1 |
| Guettrot-Imbert, G | 2 |
| Cohen, P | 1 |
| Régent, A | 1 |
| Piette, JC | 2 |
| Jallouli, M | 1 |
| Costedoat-Chalumeau, N | 4 |
| Defoort-Dhellemmes, S | 1 |
| Gunasekera, CD | 1 |
| Gupta, N | 1 |
| Zaidi, FH | 2 |
| Rennie, CA | 2 |
| Drinkwater, AK | 2 |
| Sahu, D | 2 |
| Akyol, E | 2 |
| Lotery, AJ | 8 |
| Dos Reis Neto, ET | 1 |
| Kakehasi, AM | 1 |
| de Medeiros Pinheiro, M | 1 |
| Ferreira, GA | 1 |
| Marques, CDL | 1 |
| da Mota, LMH | 1 |
| Dos Santos Paiva, E | 1 |
| Pileggi, GCS | 1 |
| Sato, EI | 1 |
| Reis, APMG | 1 |
| Xavier, RM | 1 |
| Provenza, JR | 1 |
| Woo, SJ | 1 |
| Park, KH | 1 |
| Lee, YK | 1 |
| Kuraitis, D | 1 |
| Murina, A | 1 |
| Marshall, E | 1 |
| Robertson, M | 1 |
| Kam, S | 1 |
| Penwarden, A | 1 |
| Riga, P | 1 |
| Davies, N | 2 |
| Yokogawa, N | 4 |
| Greenberg, PB | 3 |
| Perlman, E | 2 |
| Gobbett, A | 2 |
| Kotagiri, A | 1 |
| Bracewell, C | 1 |
| Smith, J | 1 |
| Chandler, LC | 1 |
| McClements, ME | 1 |
| Barnard, AR | 1 |
| MacLaren, RE | 1 |
| Xue, K | 1 |
| Dadhaniya, NV | 1 |
| Sood, I | 1 |
| Patil, A | 1 |
| Mallaiah, U | 1 |
| Upadhyaya, S | 1 |
| Handa, R | 1 |
| Gupta, SJ | 1 |
| Stremmel, C | 1 |
| Kellnar, A | 1 |
| Massberg, S | 1 |
| Kääb, S | 1 |
| Bubb, MR | 1 |
| Paniri, A | 1 |
| Hosseini, MM | 1 |
| Rasoulinejad, A | 1 |
| Akhavan-Niaki, H | 1 |
| Troldborg, A | 1 |
| Bay-Laurberg, T | 1 |
| Clemmensen, K | 1 |
| Andersen, J | 2 |
| Deleuran, B | 1 |
| Tarakcioglu, HN | 1 |
| Ozkaya, A | 1 |
| Yigit, U | 1 |
| Ohno-Tanaka, A | 2 |
| Hashiguchi, M | 2 |
| Shimizu, M | 2 |
| Ozawa, H | 2 |
| Ueno, S | 2 |
| Shinoda, K | 2 |
| Hasan, H | 1 |
| Price, EJ | 1 |
| Greenstein, VC | 3 |
| Lima de Carvalho, JR | 1 |
| Parmann, R | 1 |
| Amaro-Quireza, L | 2 |
| Lee, W | 2 |
| Hood, DC | 2 |
| Tsang, SH | 2 |
| Sparrow, JR | 1 |
| Pareek, A | 1 |
| Chandrashekara, S | 1 |
| Mehta, RT | 1 |
| Seo, EJ | 1 |
| Kim, JG | 2 |
| Yoon, YH | 2 |
| Lee, JY | 2 |
| Law, LS | 1 |
| Lo, EA | 1 |
| Yeoh, SF | 1 |
| Martín-Iglesias, D | 2 |
| Artaraz, J | 2 |
| AlAhmed, O | 1 |
| Way, A | 1 |
| Akoghlanian, S | 1 |
| Barbar-Smiley, F | 1 |
| Lemle, S | 1 |
| MacDonald, D | 1 |
| Frost, E | 1 |
| Wise, K | 1 |
| Lee, L | 1 |
| Ardoin, SP | 1 |
| Sivaraman, V | 1 |
| Foot, B | 2 |
| Hipolito-Fernandes, D | 1 |
| Luís, ME | 1 |
| Flores, R | 1 |
| Anjos, R | 1 |
| Rosenbaum, JT | 2 |
| Costenbader, KH | 2 |
| Desmarais, J | 1 |
| Fett, N | 2 |
| Goodman, SM | 1 |
| O'Dell, JR | 1 |
| Schmajuk, G | 1 |
| Werth, VP | 2 |
| Bukhari, M | 1 |
| Santilli, CM | 1 |
| Maxey, AG | 1 |
| Lattery, CA | 1 |
| Carpel, EF | 1 |
| Armbrust, KR | 1 |
| Sonido, MT | 1 |
| Rallah-Baker, K | 1 |
| Gupta, M | 1 |
| Manoj, M | 1 |
| Sahoo, RR | 1 |
| Singh, A | 1 |
| Hazarika, K | 1 |
| Bafna, P | 1 |
| Kaur, A | 1 |
| Wakhlu, A | 1 |
| Latheef, F | 1 |
| Ardern-Jones, M | 1 |
| Kabataş, N | 1 |
| Özateş, S | 1 |
| Avarisli, NA | 1 |
| Kakil, SB | 1 |
| Özişler, C | 1 |
| Osmani, Z | 1 |
| Schrama, TJ | 1 |
| Zacouris-Verweij, W | 1 |
| Frankel, S | 1 |
| Bultink, IEM | 1 |
| Cornet, A | 1 |
| van Vollenhoven, RF | 1 |
| Fambuena-Muedra, I | 1 |
| Jiménez-García, M | 1 |
| Hershko, S | 1 |
| Altemir-Gómez, I | 1 |
| Tobarra-López, A | 1 |
| Sakai, T | 1 |
| Fujinami, K | 1 |
| Kondo, M | 1 |
| Kao, JH | 1 |
| Lan, TY | 1 |
| Li, KJ | 1 |
| Wang, G | 1 |
| Zhuo, N | 1 |
| Liao, Z | 1 |
| Qi, W | 1 |
| Tian, F | 1 |
| Wen, Z | 1 |
| Nair, AA | 1 |
| Guiot, A | 2 |
| Couturier, M | 2 |
| Tebib, JG | 2 |
| Abouaf, L | 2 |
| Coury, F | 2 |
| Hambly, R | 1 |
| Lally, A | 1 |
| Tucker, WR | 1 |
| Walsh, S | 1 |
| Kan, E | 1 |
| Yakar, K | 1 |
| Demirag, MD | 1 |
| Gok, M | 1 |
| Hong, EH | 1 |
| Lim, HW | 3 |
| Schreiber, K | 2 |
| Stach, K | 1 |
| Sciascia, S | 1 |
| Hunt, BJ | 2 |
| Yates, M | 1 |
| Malaiya, R | 1 |
| Stack, J | 1 |
| Galloway, JB | 1 |
| Telek, HH | 2 |
| Yesilirmak, N | 2 |
| Sungur, G | 2 |
| Ozdemir, Y | 2 |
| Yesil, NK | 2 |
| Ornek, F | 2 |
| Kim, JW | 1 |
| Kim, YY | 1 |
| Lee, H | 1 |
| Park, SH | 1 |
| Kim, SK | 1 |
| Choe, JY | 1 |
| Joung, JY | 1 |
| Wiacek, MP | 1 |
| Bobrowska-Snarska, D | 1 |
| Lubiński, W | 1 |
| Brzosko, M | 1 |
| Modrzejewska, M | 1 |
| Couturier, A | 2 |
| Giocanti-Aurégan, A | 2 |
| Dupas, B | 1 |
| Girmens, JF | 2 |
| Le Mer, Y | 2 |
| Massamba, N | 3 |
| Barreau, E | 2 |
| Audo, I | 2 |
| Chew, AL | 1 |
| Sampson, DM | 1 |
| Chelva, E | 1 |
| Khan, JC | 1 |
| Chen, FK | 1 |
| Perlman, EM | 1 |
| Browning, D | 1 |
| Friday, RP | 1 |
| Miller, JW | 1 |
| Nti, AA | 1 |
| Serrano, LW | 1 |
| Sandhu, HS | 1 |
| Uyhazi, KE | 1 |
| Edelstein, ID | 1 |
| Zhou, EJ | 1 |
| Bowman, S | 1 |
| Song, D | 1 |
| Gangadhar, TC | 1 |
| Schuchter, LM | 1 |
| Mitnick, S | 1 |
| Huang, A | 1 |
| Nichols, CW | 1 |
| Amaravadi, RK | 1 |
| Kim, BJ | 1 |
| Aleman, TS | 1 |
| Saurabh, K | 1 |
| Roy, R | 1 |
| Thomas, NR | 1 |
| Chowdhury, M | 1 |
| Hernández Bel, L | 1 |
| Monferrer Adsuara, C | 1 |
| Hernández Garfella, M | 1 |
| Cervera Taulet, E | 1 |
| Eren, M | 1 |
| Kucukevcilioglu, M | 1 |
| Durukan, AH | 1 |
| Abdulaziz, N | 1 |
| Shah, AR | 1 |
| McCune, WJ | 1 |
| Ledingham, JM | 1 |
| MacPhie, E | 1 |
| Arndt, C | 1 |
| Costantini, M | 1 |
| Chiquet, C | 1 |
| Afriat, M | 1 |
| Berthemy, S | 1 |
| Ducasse, A | 1 |
| Allard, A | 2 |
| Healy, R | 2 |
| Bristow, E | 2 |
| Hickey, S | 2 |
| Allahdina, AM | 2 |
| Stetson, PF | 1 |
| Vitale, S | 2 |
| Wong, WT | 3 |
| Chew, EY | 2 |
| Ferris, FL | 2 |
| Sieving, PA | 2 |
| Cukras, C | 2 |
| Kim, DG | 1 |
| Yoon, CK | 1 |
| Kim, HW | 1 |
| Lee, SJ | 1 |
| Eldeeb, M | 1 |
| Chan, EW | 1 |
| Omar, A | 1 |
| Shippey, EA | 1 |
| Wagler, VD | 1 |
| Collamer, AN | 1 |
| Ardern-Jones, MR | 1 |
| Watson, SL | 1 |
| Yelf, C | 1 |
| Burdon, MA | 1 |
| Bishop, PN | 1 |
| Conigliaro, P | 1 |
| Triggianese, P | 1 |
| Draghessi, G | 1 |
| Canofari, C | 1 |
| Aloe, G | 1 |
| Chimenti, MS | 1 |
| Valeri, C | 1 |
| Nucci, C | 1 |
| Perricone, R | 2 |
| Cesareo, M | 1 |
| Fuzzard, DRW | 1 |
| Symons, RCA | 1 |
| Heriot, WJ | 1 |
| Lu, N | 1 |
| Rai, SK | 1 |
| Young, LH | 2 |
| Esdaile, JM | 2 |
| Urowitz, MB | 1 |
| Askanase, A | 1 |
| Choi, H | 1 |
| Hughes, G | 1 |
| Cabael, L | 1 |
| Rayess, N | 1 |
| Patel, VR | 1 |
| Dammacco, R | 1 |
| Procaccio, P | 1 |
| Racanelli, V | 1 |
| Vacca, A | 1 |
| Dammacco, F | 1 |
| Lee, SU | 1 |
| Lee, SH | 2 |
| Ruberto, G | 1 |
| Bruttini, C | 1 |
| Tinelli, C | 1 |
| Cavagna, L | 1 |
| Bianchi, A | 1 |
| Milano, G | 1 |
| Bulut, M | 1 |
| Akıdan, M | 1 |
| Gözkaya, O | 1 |
| Erol, MK | 1 |
| Cengiz, A | 1 |
| Çay, HF | 1 |
| Ugwuegbu, O | 1 |
| Uchida, A | 1 |
| Singh, RP | 5 |
| Beven, L | 1 |
| Hu, M | 1 |
| Kaiser, S | 1 |
| Srivastava, SK | 1 |
| Ehlers, JP | 4 |
| Ozek, D | 1 |
| Onen, M | 1 |
| Karaca, EE | 1 |
| Omma, A | 1 |
| Kemer, OE | 1 |
| Coskun, C | 1 |
| Iftikhar, M | 1 |
| Kaur, R | 1 |
| Nefalar, A | 1 |
| Usmani, B | 1 |
| Kherani, S | 1 |
| Rashid, I | 1 |
| Schönbach, E | 1 |
| Scholl, HPN | 1 |
| Shah, SM | 2 |
| Lai, SW | 1 |
| Lin, CL | 1 |
| Liao, KF | 1 |
| Kosic Knez, N | 1 |
| Šiško, K | 1 |
| Holc, I | 1 |
| Pahor, D | 1 |
| Pahor, A | 1 |
| Gracner, T | 1 |
| Jorge, A | 1 |
| Ung, C | 1 |
| Goker, YS | 1 |
| Ucgul Atılgan, C | 1 |
| Tekin, K | 1 |
| Kızıltoprak, H | 1 |
| Yetkin, E | 1 |
| Yesil Karahan, N | 1 |
| Koc, M | 1 |
| Kosekahya, P | 1 |
| Piggott, KD | 1 |
| Apte, R | 1 |
| Grassi, MA | 1 |
| Maker, MP | 1 |
| Gil, P | 1 |
| Nunes, A | 1 |
| Farinha, C | 1 |
| Teixeira, D | 1 |
| Pires, I | 1 |
| Silva, R | 1 |
| Pasaoglu, I | 1 |
| Onmez, FE | 1 |
| Sandhu, VK | 1 |
| Goel, N | 1 |
| Duro, T | 1 |
| Chen, KG | 1 |
| Alvarez, JA | 1 |
| Fonollosa, A | 1 |
| Ugarte, A | 1 |
| Arteagabeitia, A | 1 |
| Garrity, ST | 1 |
| Jung, JY | 1 |
| Zambrowski, O | 1 |
| Pichi, F | 1 |
| Su, D | 1 |
| Arya, M | 1 |
| Waheed, NK | 1 |
| Duker, JS | 2 |
| Chetrit, Y | 1 |
| Giuffrè, C | 1 |
| Kaden, TR | 1 |
| Freund, KB | 2 |
| Sarraf, D | 1 |
| Forte, R | 1 |
| Haulani, H | 1 |
| Dyrda, A | 1 |
| Jürgens, I | 1 |
| Cakir, A | 1 |
| Ozturan, ŞG | 1 |
| Yildiz, D | 1 |
| Erden, B | 1 |
| Bolukbasi, S | 1 |
| Tascilar, EK | 1 |
| Yanmaz, MN | 1 |
| Elcioglu, MN | 1 |
| Yen, CY | 1 |
| Lee, PH | 1 |
| Yen, JC | 1 |
| Chen, CC | 1 |
| Hu, HY | 1 |
| Tseng, PC | 1 |
| Zone Abid, I | 1 |
| Kaibi, I | 1 |
| Turki, R | 1 |
| Gargouri, S | 1 |
| Feki, J | 1 |
| Proano, C | 1 |
| Kimball, GP | 1 |
| Tsang, AC | 2 |
| Ahmadi, S | 1 |
| Hamilton, J | 2 |
| Gao, J | 1 |
| Coupland, SG | 2 |
| Gottlieb, CC | 2 |
| Solberg, Y | 1 |
| Dysli, C | 1 |
| Möller, B | 1 |
| Wolf, S | 1 |
| Zinkernagel, MS | 1 |
| Uğurlu, A | 1 |
| Aslanova, M | 1 |
| Cebeci, Z | 1 |
| Kır Mercül, N | 1 |
| Sauer, L | 1 |
| Calvo, CM | 1 |
| Vitale, AS | 1 |
| Henrie, N | 1 |
| Milliken, CM | 1 |
| Bernstein, PS | 1 |
| Yaylali, SA | 1 |
| Sadigov, F | 1 |
| Erbil, H | 1 |
| Ekinci, A | 1 |
| Akcakaya, AA | 1 |
| Stelton, CR | 1 |
| Connors, DB | 1 |
| Walia, SS | 1 |
| Walia, HS | 1 |
| Gorovoy, IR | 2 |
| Gorovoy, MS | 2 |
| Modjtahedi, BS | 1 |
| Movassagh, N | 1 |
| Gandhi, N | 1 |
| Morse, LS | 1 |
| Maibach, HI | 2 |
| Ulviye, Y | 1 |
| Betul, T | 1 |
| Nur, TH | 1 |
| Selda, C | 1 |
| Chien, FY | 1 |
| Johnson, MW | 1 |
| Jivrajka, RV | 1 |
| Genead, MA | 1 |
| McAnany, JJ | 1 |
| Chow, CC | 1 |
| Mieler, WF | 4 |
| Lyons, JS | 4 |
| Mititelu, M | 2 |
| Wong, BJ | 1 |
| Brenner, M | 1 |
| Bryar, PJ | 1 |
| Jampol, LM | 3 |
| Fawzi, AA | 3 |
| Buscombe, CP | 1 |
| Lin, S | 1 |
| Wilson-Holt, NJ | 1 |
| Martínez-Costa, L | 2 |
| Victoria Ibañez, M | 1 |
| Murcia-Bello, C | 2 |
| Epifanio, I | 2 |
| Verdejo-Gimeno, C | 2 |
| Beltrán-Catalán, E | 2 |
| Marco-Ventura, P | 2 |
| Dunogué, B | 1 |
| Trentini, FJ | 1 |
| Ibañez, MV | 1 |
| Hu, J | 2 |
| Nika, M | 1 |
| Blachley, TS | 1 |
| Edwards, P | 1 |
| Lee, PP | 1 |
| Stein, JD | 1 |
| Graves, GS | 1 |
| Adam, MK | 2 |
| Stepien, KE | 3 |
| Han, DP | 3 |
| Chiang, E | 1 |
| Barnes, AC | 1 |
| Bhavsar, KV | 2 |
| Weber, ML | 1 |
| Witkin, AJ | 1 |
| Scholl, HP | 1 |
| Phillips, BN | 1 |
| Chun, DW | 1 |
| Lee, MG | 2 |
| Kim, SJ | 2 |
| Ham, DI | 2 |
| Kang, SW | 2 |
| Kee, C | 1 |
| Lee, J | 2 |
| Cha, HS | 2 |
| Koh, EM | 1 |
| Asensio-Sánchez, VM | 1 |
| Huynh, N | 2 |
| Abraham, ES | 1 |
| Ramachandran, R | 1 |
| Johnston, JL | 1 |
| Darvill, P | 1 |
| Thomson, GT | 1 |
| Walvick, MD | 2 |
| Ngo, CH | 2 |
| Lee, DH | 1 |
| Joe, SG | 1 |
| Lee, CK | 1 |
| Yoo, B | 1 |
| Koo, BS | 1 |
| Kim, JT | 1 |
| Ahmadi Pirshahid, S | 1 |
| Mukkamala, LK | 1 |
| Jaumouillé, S | 1 |
| Espargillière, D | 1 |
| Mouriaux, F | 1 |
| Mortemousque, B | 1 |
| Debellemanière, G | 1 |
| Flores, M | 1 |
| Tumahai, P | 1 |
| Meillat, M | 1 |
| Bidaut Garnier, M | 1 |
| Delbosc, B | 1 |
| Saleh, M | 1 |
| Rubin, DL | 1 |
| Moschos, MM | 2 |
| Nitoda, E | 1 |
| Chatziralli, IP | 1 |
| Gatzioufas, Z | 1 |
| Koutsandrea, C | 1 |
| Kitsos, G | 1 |
| Au, A | 3 |
| Parikh, V | 1 |
| Modi, YS | 4 |
| Schachat, AP | 3 |
| Leung, LS | 1 |
| Neal, JW | 1 |
| Wakelee, HA | 1 |
| Sequist, LV | 1 |
| Itoh, Y | 1 |
| Vasanji, A | 1 |
| Nõupuu, K | 1 |
| Zernant, J | 1 |
| Tsang, S | 1 |
| Allikmets, R | 1 |
| Ding, HJ | 1 |
| Denniston, AK | 1 |
| Rao, VK | 1 |
| Robinson, M | 1 |
| Shah, VA | 1 |
| Motarjemizadeh, Q | 1 |
| Aidenloo, NS | 1 |
| Abbaszadeh, M | 1 |
| Sanabria, MR | 1 |
| Toledo-Lucho, SC | 1 |
| Sellam, A | 1 |
| Le Hoang, P | 1 |
| Bodaghi, B | 3 |
| Navajas, EV | 1 |
| Krema, H | 1 |
| Hammoudi, DS | 1 |
| Lipton, JH | 1 |
| Simpson, ER | 1 |
| Boyd, S | 1 |
| Neamtu, DV | 1 |
| Eller, AW | 1 |
| Cohen, SY | 1 |
| Fine, HF | 1 |
| Lai, TY | 4 |
| Pawlak-Buś, K | 1 |
| Gaca-Wysocka, M | 1 |
| Grzybowski, A | 1 |
| Leszczyński, P | 1 |
| Mount, GR | 1 |
| Youssef, J | 1 |
| Lin, P | 1 |
| Iselin, KC | 1 |
| Marti, P | 1 |
| Pless, M | 1 |
| Weinlander, E | 1 |
| Ringeisen, AL | 1 |
| Parikh, VS | 2 |
| Kim, JE | 1 |
| Shulman, S | 1 |
| Wollman, J | 1 |
| Brikman, S | 1 |
| Padova, H | 1 |
| Elkayam, O | 1 |
| Paran, D | 1 |
| McClellan, AJ | 1 |
| Chang, JS | 1 |
| Smiddy, WE | 1 |
| Rodstrom, T | 1 |
| Babeau, F | 1 |
| Busetto, T | 1 |
| Hamel, C | 1 |
| Villain, M | 1 |
| Daien, V | 1 |
| Gilhooley, E | 1 |
| Feighery, C | 1 |
| Collins, SM | 1 |
| Ponticelli, C | 1 |
| Moroni, G | 1 |
| Eo, DR | 1 |
| Koh, E | 1 |
| Braslow, RA | 1 |
| Shiloach, M | 1 |
| Macsai, MS | 1 |
| Latasiewicz, M | 1 |
| Gourier, H | 1 |
| Luqmani, R | 2 |
| Murray, JJ | 1 |
| Lee, MS | 2 |
| Arendt, P | 1 |
| Gerding, H | 1 |
| Sharma, S | 1 |
| Youssef, MM | 1 |
| El-Fayoumi, D | 1 |
| Sidky, MK | 1 |
| Hegazy, AI | 1 |
| Marzouk, H | 1 |
| Eltanamly, RM | 1 |
| Semmer, AE | 1 |
| Harrison, AR | 1 |
| Olsen, TW | 1 |
| Vavvas, D | 1 |
| Pasquale, L | 1 |
| Berson, EL | 2 |
| Chiffoleau, A | 1 |
| Guillet, A | 1 |
| Zanlonghi, X | 1 |
| Jolliet, P | 1 |
| Turgut, B | 1 |
| Turkcuoglu, P | 1 |
| Serdar Koca, S | 1 |
| Aydemir, O | 1 |
| Nebbioso, M | 2 |
| Grenga, R | 1 |
| Karavitis, P | 1 |
| Pasadhika, S | 2 |
| Fishman, GA | 2 |
| Anderson, C | 2 |
| Pahk, P | 1 |
| Blaha, GR | 2 |
| Spindel, GP | 1 |
| Alster, Y | 1 |
| Rafaeli, O | 1 |
| Marx, JL | 2 |
| Pluta, JP | 1 |
| Rüther, K | 3 |
| Schell, J | 1 |
| Godara, P | 1 |
| Rha, J | 1 |
| Carroll, J | 1 |
| Choi, D | 1 |
| Shahidi, M | 1 |
| Salu, P | 1 |
| Uvijls, A | 1 |
| van den Brande, P | 1 |
| Ojaimi, E | 1 |
| Guymer, RH | 1 |
| Wong, TY | 1 |
| Harper, CA | 1 |
| Livani, ML | 1 |
| Steigerwalt, RD | 1 |
| Panetta, V | 1 |
| Rispoli, E | 1 |
| Wolfe, F | 1 |
| Payne, JF | 1 |
| Hubbard, GB | 1 |
| Aaberg, TM | 1 |
| Yan, J | 1 |
| Kobak, S | 1 |
| Deveci, H | 1 |
| Karkanová, M | 1 |
| Matusková, V | 1 |
| Vlková, E | 1 |
| Dosková, H | 1 |
| Uhmannová, R | 1 |
| Bergholz, R | 1 |
| Schroeter, J | 2 |
| Michaelides, M | 1 |
| Stover, NB | 1 |
| Francis, PJ | 1 |
| Weleber, RG | 2 |
| Tanga, L | 1 |
| Centofanti, M | 1 |
| Oddone, F | 1 |
| Parravano, M | 1 |
| Parisi, V | 1 |
| Ziccardi, L | 1 |
| Kroegler, B | 1 |
| Manni, G | 1 |
| Hodson, TJ | 1 |
| Aliferis, K | 1 |
| Mermoud, C | 1 |
| Safran, AB | 1 |
| Flach, AJ | 2 |
| Walvick, MP | 1 |
| Tongson, E | 1 |
| Lee, WJ | 1 |
| Ko, MK | 1 |
| Hickley, NM | 1 |
| Al-Maskari, A | 1 |
| McKibbin, M | 1 |
| Ingster-Moati, I | 3 |
| Fardeau, C | 1 |
| Benveniste, O | 1 |
| Simon, C | 1 |
| Pulido, JS | 1 |
| Leavitt, JA | 1 |
| Lewis, RA | 2 |
| Missner, S | 1 |
| Covert, DJ | 1 |
| Tang, C | 1 |
| Godfrey, T | 1 |
| Stawell, R | 1 |
| Vanderzee, G | 1 |
| Tassi, D | 1 |
| Yülek, F | 1 |
| Uğurlu, N | 1 |
| Akçay, E | 1 |
| Kocamış, Sİ | 1 |
| Gerçeker, S | 1 |
| Erten, Ş | 1 |
| Midillioğlu, İ | 1 |
| Şimşek, Ş | 1 |
| Blomquist, PH | 1 |
| Chundru, RK | 1 |
| Mavrikakis, I | 1 |
| Sfikakis, PP | 2 |
| Mavrikakis, E | 1 |
| Rougas, K | 1 |
| Nikolaou, A | 1 |
| Kostopoulos, C | 1 |
| Mavrikakis, M | 2 |
| Pineau, C | 1 |
| Joseph, L | 1 |
| Clarke, A | 1 |
| Penrose, PJ | 1 |
| Tzekov, RT | 2 |
| Sutter, EE | 1 |
| Fu, AD | 1 |
| Allen, AW | 1 |
| Fung, WE | 1 |
| Oxford, KW | 1 |
| Rivett, K | 1 |
| Moschos, MN | 1 |
| Apostolopoulos, M | 1 |
| Mallias, JA | 1 |
| Bouros, C | 1 |
| Theodossiadis, GP | 1 |
| Serrato, A | 1 |
| Maturi, RK | 2 |
| Yu, M | 1 |
| Cimaz, R | 1 |
| Brucato, A | 1 |
| Meregalli, E | 1 |
| Muscará, M | 1 |
| Sergi, P | 1 |
| Whitelaw, D | 1 |
| Jessop, S | 1 |
| Lee, AG | 1 |
| Almony, A | 1 |
| Garg, S | 1 |
| Peters, RK | 1 |
| Mamet, R | 1 |
| Tsong, J | 1 |
| Shibuya, B | 1 |
| Kitridou, R | 1 |
| Sadun, AA | 1 |
| Bui Quoc, E | 2 |
| Rigolet, MH | 1 |
| Chosidow, O | 1 |
| Chan, WM | 2 |
| Li, H | 1 |
| Lai, RY | 1 |
| Lam, DS | 2 |
| Tripp, JM | 1 |
| Ngai, JW | 1 |
| Renner, AB | 1 |
| Tillack, H | 1 |
| Fraser, CM | 1 |
| Crochet, M | 1 |
| Orssaud, C | 1 |
| Dufier, JL | 1 |
| Roche, O | 1 |
| Yam, JC | 1 |
| Kwok, AK | 1 |
| Severns, ML | 2 |
| Rodriguez-Padilla, JA | 1 |
| Hedges, TR | 1 |
| Monson, B | 1 |
| Srinivasan, V | 1 |
| Wojtkowski, M | 1 |
| Reichel, E | 1 |
| Schuman, JS | 1 |
| Fujimoto, JG | 1 |
| Foerster, J | 1 |
| Berndt, S | 1 |
| Hanna, B | 1 |
| Holdeman, NR | 1 |
| Tang, RA | 1 |
| Schiffman, JS | 1 |
| Portnoy, JZ | 1 |
| Callen, JP | 1 |
| Douche, C | 1 |
| Bechetoille, A | 1 |
| Ebran, JM | 1 |
| Hart, WM | 1 |
| Burde, RM | 1 |
| Johnston, GP | 1 |
| Drews, RC | 1 |
| Lanham, JG | 1 |
| Hughes, GR | 1 |
| Bunch, TW | 1 |
| O'Duffy, JD | 1 |
| Bernstein, HN | 2 |
| Rynes, RI | 4 |
| Mackenzie, AH | 1 |
| Mills, PV | 2 |
| Beck, M | 1 |
| Power, BJ | 1 |
| Olansky, AJ | 1 |
| Tobin, DR | 1 |
| Krohel, G | 1 |
| Neumann, R | 1 |
| Foster, CS | 1 |
| Cox, NH | 1 |
| Paterson, WD | 1 |
| Aylward, JM | 1 |
| Potter, B | 1 |
| Ochsendorf, FR | 3 |
| Runne, U | 3 |
| Goerz, G | 1 |
| Zrenner, E | 1 |
| Falcone, PM | 1 |
| Paolini, L | 1 |
| Lou, PL | 1 |
| Spalton, DJ | 1 |
| Grierson, DJ | 1 |
| Shipley, M | 2 |
| Silman, A | 2 |
| Levy, GD | 1 |
| Munz, SJ | 1 |
| Paschal, J | 1 |
| Cohen, HB | 1 |
| Pince, KJ | 1 |
| Peterson, T | 1 |
| Block, JA | 1 |
| Blyth, C | 1 |
| Lane, C | 1 |
| Clarke, AK | 1 |
| May, K | 1 |
| Metcalf, T | 1 |
| Gough, A | 1 |
| Wang, C | 1 |
| Li, Y | 1 |
| Panaritis, T | 1 |
| Gans, M | 1 |
| Folk, JC | 1 |
| Nichols, B | 1 |
| Oetting, TT | 1 |
| Kardon, RH | 1 |
| Thorne, JE | 1 |
| Maguire, AM | 1 |
| Bienfang, D | 1 |
| Coblyn, JS | 1 |
| Liang, MH | 1 |
| Corzillius, M | 1 |
| Coyle, JT | 1 |
| Shroyer, NF | 1 |
| Lupski, JR | 1 |
| Fraenkel, L | 1 |
| Felson, DT | 1 |
| Wei, LC | 1 |
| Chen, SN | 1 |
| Ho, CL | 1 |
| Kuo, YH | 1 |
| Ho, JD | 1 |
| Carr, RE | 1 |
| Farjo, AA | 1 |
| Brinkley, JR | 1 |
| Dubois, EL | 1 |
| Ryan, SJ | 1 |
| Chylack, LT | 1 |
| Bienfang, DC | 1 |
| Bellows, AR | 1 |
| Stillman, JS | 1 |
| Weiner, A | 1 |
| Sandberg, MA | 1 |
| Gaudio, AR | 1 |
| Kini, MM | 1 |
| Ruiz, RS | 1 |
| Saatci, OA | 1 |
| Morsman, CD | 1 |
| Livesey, SJ | 1 |
| Richards, IM | 1 |
| Jessop, JD | 1 |
| Gottlieb, NL | 1 |
| Bishara, SA | 1 |
| Matamoros, N | 1 |
| Moschos, M | 1 |
| Brouza, D | 1 |
| Panagakis, E | 1 |
| Niemeyer, G | 1 |
| Früh, B | 1 |
| Lozier, JR | 1 |
| Friedlaender, MH | 1 |
| Raines, MF | 1 |
| Bhargava, SK | 1 |
| Rosen, ES | 1 |
| Terrell, WL | 1 |
| Haik, KG | 1 |
| Haik, GM | 1 |
| Rossi, A | 1 |
| Rinaldi, M | 1 |
| Vozza, A | 1 |
| Romano, A | 1 |
| Turco, P | 1 |
| Franchi, A | 1 |
| Magni, R | 1 |
| Lodigiani, L | 1 |
| Cordella, M | 1 |
| Finbloom, DS | 1 |
| Silver, K | 1 |
| Newsome, DA | 1 |
| Gunkel, R | 1 |
| Henkind, P | 1 |
| Gold, DH | 1 |
| Zvaifler, NJ | 1 |
| Legros, J | 1 |
| Rosner, I | 1 |
| Berger, C | 1 |
| Brown, RK | 1 |
| François, J | 1 |
| de Rouck, A | 1 |
| Cambie, E | 1 |
| de Laey, JJ | 1 |
| Petrohelos, MA | 1 |
| Yonemura, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics[NCT04353271] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2020-04-17 | Terminated (stopped due to FDA recommendations to not use outside of the hospital setting or in a clinical trial due to the risk of cardiac arrhythmias) | ||
| Hydroxychloroquine Exposure in Systemic Lupus Erythematosus (SLE)[NCT03802188] | 3,700 participants (Anticipated) | Observational | 2018-05-09 | Recruiting | |||
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam[NCT04328493] | Phase 2 | 10 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope[NCT04361318] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | ||
| A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults[NCT04370262] | Phase 3 | 233 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| Posterior Segment Evaluation of Patients With Systemic Lupus Erythematosus Using Optical Coherence Tomography and Optical Coherence Tomography Angiography[NCT04866615] | 150 participants (Anticipated) | Observational | 2021-06-04 | Recruiting | |||
| Randomized Controlled Trial Testing the Effect of Hydroxychloroquine Combined With Low-dose Corticosteroid Therapy in Pulmonary Sarcoidosis[NCT05247554] | Phase 3 | 200 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial[NCT04491994] | Phase 3 | 540 participants (Actual) | Interventional | 2020-04-10 | Completed | ||
| Metabolic Effects of Hydroxychloroquine[NCT02026232] | 21 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to COVID-19 & loss of funding) | |||
| Genotype - Phenotype Study of Patients With Plaquenil-induced Retinal Toxicity[NCT01145196] | 300 participants (Anticipated) | Observational | 2010-08-23 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects in each arm who are hospitalized for Covid 19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Nasopharyngeal swab PCR measurement of viral load expressed as the % of negative PCR swabs (NCT04353271)
Timeframe: 7 days after initiation of trial
| Intervention | participants (Number) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who die secondary to Covid-19 infection (NCT04353271)
Timeframe: 70 Days (10 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 0 |
Number of subjects in each arm who discontinue or withdraw medication use for any reason (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 0 |
| Control | 1 |
Number of subjects in each arm who have confirmed Covid-19 infection (NCT04353271)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
| Control | 2 |
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
After start of treatment, development of fever > 101 F for > 72 hours, shortness of breath by minimal exertion (10-Step walk test), derangement of basic lab parameters (ALC < 1000 or raised CRP) or appearance of infiltrates on CXR during course of treatment was labeled as progression irrespective of PCR status (NCT04491994)
Timeframe: 5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care (SOC) | 5 |
| Intervention Group | 11 |
determined by fasting blood glucose performed at baseline and follow-up (NCT02026232)
Timeframe: 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline Glucose (mg/dL) | Follow-up Glucose (mg/dL) | |
| Hydroxychloroquine | 186.9 | 165.9 |
| Placebo | 163.1 | 158.8 |
determined by lipid profile with calculated LDL performed at baseline and follow-up (NCT02026232)
Timeframe: 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline - LDL (mg/dL) | Follow-up - LDL (mg/dL) | |
| Hydroxychloroquine | 90.4 | 72.4 |
| Placebo | 92.8 | 87.7 |
51 reviews available for hydroxychloroquine and Retinal Diseases
| Article | Year |
|---|---|
Hydroxychloroquine in dermatology: New perspectives on an old drug.
Topics: Dermatology; Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Mass Screening; Monitorin | 2020 |
Hydroxychloroquine Retinopathy in the Era of Advanced Imaging Modalities.
Topics: Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Drug-Related Side Effects and Adverse | 2020 |
Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now?
Topics: Academies and Institutes; Antirheumatic Agents; Electroretinography; Humans; Hydroxychloroquine; Pra | 2020 |
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Topics: Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; | 2020 |
Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines.
Topics: Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Ophthalmo | 2020 |
Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy.
Topics: Animals; Betacoronavirus; Chloroquine; Dependovirus; Genetic Therapy; Humans; Hydroxychloroquine; Im | 2020 |
Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.
Topics: Arrhythmias, Cardiac; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Hu | 2020 |
Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations.
Topics: Betacoronavirus; Cytochrome P-450 Enzyme System; Epigenesis, Genetic; Humans; Hydroxychloroquine; Is | 2020 |
[Hydroxychloroquine treatment rarely causes eye damage when used correctly].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Lupus Erythematosus | 2020 |
What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects.
Topics: Antimalarials; Caregivers; Chloroquine; COVID-19 Drug Treatment; Drug-Related Side Effects and Adver | 2021 |
What is new in recommendations on ophthalmological screening in patients treated with chloroquine and hydroxychloroquine? Update and literature review.
Topics: Antimalarials; Chloroquine; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Mas | 2017 |
[Update on recommendations for screening for hydroxychloroquine retinopathy].
Topics: Antimalarials; Diagnostic Techniques, Ophthalmological; Dose-Response Relationship, Drug; Humans; Hy | 2017 |
Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.
Topics: Antirheumatic Agents; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Drug Administ | 2018 |
Hydroxychloroquine: An old drug with new relevance.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythemato | 2018 |
The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary.
Topics: Chloroquine; Clinical Protocols; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine | 2018 |
Hydroxychloroquine retinopathy - implications of research advances for rheumatology care.
Topics: Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Practic | 2018 |
Intravitreal dexamethasone implant therapy for the treatment of cystoid macular Oedema due to hydroxychloroquine retinopathy: a case report and literature review.
Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Implants; Female; Glucocorticoids; Humans; Hydroxychlo | 2018 |
Hydrochloroquine retinopathy: characteristic presentation with review of screening.
Topics: Aged; Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Female; Humans; Hydroxychloroqu | 2013 |
Hydroxychloroquine: a multifaceted treatment in lupus.
Topics: Antimalarials; Antirheumatic Agents; Biomarkers; Half-Life; Humans; Hydroxychloroquine; Interferon-a | 2014 |
Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test.
Topics: Antirheumatic Agents; Chloroquine; Electroretinography; Fluorescein Angiography; Humans; Hydroxychlo | 2015 |
Hydroxychloroquine-related retinal toxicity.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Optical Imaging; Retinal Diseases; Rheumatic Disea | 2016 |
Hydroxychloroquine retinopathy: A review of imaging.
Topics: Antimalarials; Electroretinography; Fluorescein Angiography; Fundus Oculi; Humans; Hydroxychloroquin | 2015 |
Hydroxychloroquine: A Brief Review on Screening, Toxicity, and Progression.
Topics: Antimalarials; Antirheumatic Agents; Disease Progression; Humans; Hydroxychloroquine; Practice Guide | 2016 |
[Current view on chloroquine derivative treatment from rheumatologist perspective and possible ocular side effects].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retinal Disea | 2016 |
Hydroxychloroquine in systemic lupus erythematosus (SLE).
Topics: Animals; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pr | 2017 |
Hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Connective Tissue Diseases; Diagnostic Techniques, Ophthalmological; Global He | 2017 |
Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy.
Topics: Antimalarials; Chloroquine; Early Diagnosis; Electroretinography; Humans; Hydroxychloroquine; Malari | 2009 |
[Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up].
Topics: Antimalarials; Chloroquine; Diagnostic Techniques, Ophthalmological; Dose-Response Relationship, Dru | 2009 |
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
Topics: Antimalarials; Carbohydrate Metabolism; Cardiovascular Diseases; Chloroquine; Clinical Trials as Top | 2012 |
Screening for antimalarial toxicity: current concepts.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases | 2002 |
Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Electroretinography; Humans; Hydr | 2005 |
Hydroxychloroquine-induced retinopathy: a dermatologic perspective.
Topics: Antimalarials; Drug Monitoring; Humans; Hydroxychloroquine; Retinal Diseases | 2006 |
Ocular toxicity of hydroxychloroquine.
Topics: Antimalarials; Color Perception; Diagnosis, Differential; Genetic Predisposition to Disease; Humans; | 2006 |
Ophthalmologic aspects of chloroquine and hydroxychloroquine therapy.
Topics: Chloroquine; Dose-Response Relationship, Drug; Electroretinography; Eye; Humans; Hydroxychloroquine; | 1983 |
Antimalarial therapy in SLE.
Topics: Antimalarials; Binding Sites; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Femal | 1982 |
Disease-modifying drugs for progressive rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aurothioglucose; Azathioprine; Chloroquine; Cyclophosphamide; Gold; Gold Sodi | 1980 |
Antimalarials and ophthalmologic safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, | 1982 |
Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity.
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retin | 1993 |
[Chloroquine retinopathy: avoidable by individualized daily dosing].
Topics: Adult; Child; Chloroquine; Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Retinal Dis | 1993 |
Retinopathy and antimalarial drugs--the British experience.
Topics: Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Ma | 1996 |
Ophthalmologic considerations in using antimalarials in the United States.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases; Safety; United States; Vis | 1996 |
Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data.
Topics: Antirheumatic Agents; Corneal Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Dru | 1997 |
Detection and prevention of maculopathy associated with antimalarial agents.
Topics: Antimalarials; Chloroquine; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Mac | 1999 |
Chloroquine and hydroxychloroquine retinopathy: how to follow affected patients.
Topics: Chloroquine; Follow-Up Studies; Fundus Oculi; Humans; Hydroxychloroquine; Photography; Retinal Disea | 1991 |
Ocular safety of hydroxychloroquine.
Topics: Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Retinal Diseases; Risk Factors; Vision | 1991 |
[Chloroquine and hydroxychloroquine: side effect profile of important therapeutic drugs].
Topics: Chloroquine; Dose-Response Relationship, Drug; Drug Administration Schedule; Half-Life; Humans; Hydr | 1991 |
[Examination strategies in the diagnosis of drug-induced retinal damage].
Topics: Chloroquine; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Risk Factors; Vision Tests | 1989 |
Complications of antimalarial therapy.
Topics: Antimalarials; Chemical Phenomena; Chemistry; Chloroquine; Ciliary Body; Color Perception; Corneal D | 1989 |
Ocular manifestations of rheumatic disorders. Natural and iatrogenic.
Topics: Adrenal Cortex Hormones; Arteritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Chloroquine; Conjunc | 1973 |
Antimalarials in the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Chloroquine; Drug Eruptions; Headache; Humans; Hydroxychloroquine; Placebos; | 1971 |
[Review of electroretinography: 1970].
Topics: Animals; Anura; Cats; Cyprinidae; Diabetes Mellitus; Dogs; Electrooculography; Electroretinography; | 1971 |
7 trials available for hydroxychloroquine and Retinal Diseases
| Article | Year |
|---|---|
FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.
Topics: Adult; Aged; Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Hydroxychloroquine; Imidazole | 2019 |
Swept source optical coherence tomography angiography in patients treated with hydroxychloroquine: correlation with morphological and functional tests.
Topics: Adult; Antirheumatic Agents; Cross-Sectional Studies; Electroretinography; Female; Fluorescein Angio | 2021 |
Spectral domain optical coherence tomography for early detection of retinal alterations in patients using hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Drug Monitoring; Early Diagnosis; Female; Humans; Hydroxychloroqu | 2013 |
Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity.
Topics: Adult; Antirheumatic Agents; Chloroquine; Cross-Sectional Studies; Electroretinography; Female; Fixa | 2013 |
Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Topics: Aged; Antineoplastic Agents; Antirheumatic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Com | 2015 |
Early retinal and retinal nerve fiber layer effects of hydroxychloroquine: a follow up study by sdOCT.
Topics: Antimalarials; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Nerve Fibers; Retina; Re | 2013 |
Evaluation of several tests in screening for chloroquine maculopathy.
Topics: Adult; Aged; Aged, 80 and over; Contrast Sensitivity; Electrooculography; Evoked Potentials, Visual; | 1989 |
355 other studies available for hydroxychloroquine and Retinal Diseases
| Article | Year |
|---|---|
Clinically effective concentration and risk of hydroxychloroquine retinopathy in systemic lupus erythematosus: walking on a thin line. Comment on the article by Garg et al.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retinal Diseases; W | 2022 |
Effect of spatial averaging on the amplitude ring ratio in multifocal electroretinography.
Topics: Electroretinography; Female; Humans; Hydroxychloroquine; Macular Degeneration; Male; Retina; Retinal | 2022 |
Impact of Structural Changes on Multifocal Electroretinography in Patients With Use of Hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; Female; Humans; Hydro | 2021 |
Screening for hydroxychloroquine retinopathy in Australia.
Topics: Antirheumatic Agents; Australia; Humans; Hydroxychloroquine; Retinal Diseases | 2021 |
A novel 5-ring multifocal electroretinography stimulus for detecting hydroxychloroquine retinal toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxych | 2022 |
Risk of hydroxychloroquine retinopathy in the community.
Topics: Antirheumatic Agents; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Human | 2022 |
Visual Field Sensitivity Prediction Using Optical Coherence Tomography Analysis in Hydroxychloroquine Toxicity.
Topics: Aged; Antirheumatic Agents; Electroretinography; Female; Fluorescein Angiography; Follow-Up Studies; | 2022 |
When should we start screening for hydroxychloroquine retinopathy?
Topics: Antirheumatic Agents; Fluorescein Angiography; Humans; Hydroxychloroquine; Retinal Diseases; Tomogra | 2022 |
RetINal Toxicity And HydroxyChloroquine Therapy (INTACT): protocol for a prospective population-based cohort study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; British Columbia; Cohort Studies; Humans; Hydrox | 2022 |
Hydroxychloroquine screening practice: a survey of doctors requesting mfERG testing.
Topics: Antirheumatic Agents; Electroretinography; Humans; Hydroxychloroquine; Retina; Retinal Diseases | 2023 |
Quantitative analysis of optical coherence tomography imaging in patients with different severities of hydroxychloroquine toxicity.
Topics: Aged; Antirheumatic Agents; Case-Control Studies; Female; Humans; Hydroxychloroquine; Male; Middle A | 2023 |
Hydroxychloroquine Causes Early Inner Retinal Toxicity and Affects Autophagosome-Lysosomal Pathway and Sphingolipid Metabolism in the Retina.
Topics: Animals; Antirheumatic Agents; Autophagosomes; Hydroxychloroquine; Lysosomes; Macular Degeneration; | 2022 |
Quantitative autofluorescence findings in patients undergoing hydroxychloroquine treatment.
Topics: Adult; Antirheumatic Agents; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Middle Age | 2022 |
Screening for hydroxychloroquine retinopathy: Current recomendations and future perspectives.
Topics: Humans; Hydroxychloroquine; Retinal Diseases; Visual Field Tests | 2022 |
MERCI: a machine learning approach to identifying hydroxychloroquine retinopathy using mfERG.
Topics: Antirheumatic Agents; Electroretinography; Humans; Hydroxychloroquine; Machine Learning; Quality of | 2022 |
Outcomes of screening for hydroxychloroquine retinopathy at the Manchester Royal Eye Hospital: 2 years' audit.
Topics: Fundus Oculi; Hospitals; Humans; Hydroxychloroquine; Ophthalmologists; Retinal Diseases | 2023 |
Unusual Presentation of Acute Hydroxychloroquine Retinopathy.
Topics: Adult; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Fluorescein An | 2023 |
Clock-hour topography and extent of outer retinal damage in hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases; Tomography, Optical Coherence; V | 2022 |
Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thicknesses in Hydroxychloroquine Retinopathy.
Topics: Cross-Sectional Studies; Humans; Hydroxychloroquine; Nerve Fibers; Retina; Retinal Diseases; Retinal | 2023 |
Visual field examinations using different strategies in Asian patients taking hydroxychloroquine.
Topics: Antirheumatic Agents; Electroretinography; Fluorescein Angiography; Humans; Hydroxychloroquine; Reti | 2022 |
[CHLOROQUINE AND HYDROXYCHLOROQUINE TOXICITY].
Topics: Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases | 2022 |
CHOROIDAL VASCULARITY INDEX IN HYDROXYCHLOROQUINE TOXIC RETINOPATHY: A Quantitative Comparative Analysis Using Enhanced Depth Imaging In Spectral Domain Optical Coherence Tomography.
Topics: Choroid; Humans; Hydroxychloroquine; Retinal Diseases; Tomography, Optical Coherence | 2023 |
Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report.
Topics: Adult; Antirheumatic Agents; Eye Diseases; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2022 |
A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom.
Topics: Antirheumatic Agents; Hospitals; Humans; Hydroxychloroquine; Retinal Diseases; United Kingdom; Visua | 2023 |
A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom.
Topics: Antirheumatic Agents; Hospitals; Humans; Hydroxychloroquine; Retinal Diseases; United Kingdom; Visua | 2023 |
A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom.
Topics: Antirheumatic Agents; Hospitals; Humans; Hydroxychloroquine; Retinal Diseases; United Kingdom; Visua | 2023 |
A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom.
Topics: Antirheumatic Agents; Hospitals; Humans; Hydroxychloroquine; Retinal Diseases; United Kingdom; Visua | 2023 |
A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom.
Topics: Antirheumatic Agents; Hospitals; Humans; Hydroxychloroquine; Retinal Diseases; United Kingdom; Visua | 2023 |
A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom.
Topics: Antirheumatic Agents; Hospitals; Humans; Hydroxychloroquine; Retinal Diseases; United Kingdom; Visua | 2023 |
A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom.
Topics: Antirheumatic Agents; Hospitals; Humans; Hydroxychloroquine; Retinal Diseases; United Kingdom; Visua | 2023 |
A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom.
Topics: Antirheumatic Agents; Hospitals; Humans; Hydroxychloroquine; Retinal Diseases; United Kingdom; Visua | 2023 |
A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom.
Topics: Antirheumatic Agents; Hospitals; Humans; Hydroxychloroquine; Retinal Diseases; United Kingdom; Visua | 2023 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
[Exogenously induced retinopathies].
Topics: Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Humans; Hydroxychloroquine; Pentosan | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
Topics: Aged; Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Sy | 2022 |
Analysis of the outer retinal thickness pixel maps for the screening of hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Cross-Sectional Studies; Humans; Hydroxychloroquine; Retina; Retinal Diseases; | 2023 |
Analysis of the outer retinal thickness pixel maps for the screening of hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Cross-Sectional Studies; Humans; Hydroxychloroquine; Retina; Retinal Diseases; | 2023 |
Analysis of the outer retinal thickness pixel maps for the screening of hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Cross-Sectional Studies; Humans; Hydroxychloroquine; Retina; Retinal Diseases; | 2023 |
Analysis of the outer retinal thickness pixel maps for the screening of hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Cross-Sectional Studies; Humans; Hydroxychloroquine; Retina; Retinal Diseases; | 2023 |
Analysis of the outer retinal thickness pixel maps for the screening of hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Cross-Sectional Studies; Humans; Hydroxychloroquine; Retina; Retinal Diseases; | 2023 |
Analysis of the outer retinal thickness pixel maps for the screening of hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Cross-Sectional Studies; Humans; Hydroxychloroquine; Retina; Retinal Diseases; | 2023 |
Analysis of the outer retinal thickness pixel maps for the screening of hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Cross-Sectional Studies; Humans; Hydroxychloroquine; Retina; Retinal Diseases; | 2023 |
Analysis of the outer retinal thickness pixel maps for the screening of hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Cross-Sectional Studies; Humans; Hydroxychloroquine; Retina; Retinal Diseases; | 2023 |
Analysis of the outer retinal thickness pixel maps for the screening of hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Cross-Sectional Studies; Humans; Hydroxychloroquine; Retina; Retinal Diseases; | 2023 |
"En Face" Spectral-Domain Optical Coherence Tomography versus Multifocal Electroretinogram in Hydroxychloroquine Retinopathy Screening.
Topics: Chloroquine; Cohort Studies; Electroretinography; Humans; Hydroxychloroquine; Prospective Studies; R | 2023 |
"En Face" Spectral-Domain Optical Coherence Tomography versus Multifocal Electroretinogram in Hydroxychloroquine Retinopathy Screening.
Topics: Chloroquine; Cohort Studies; Electroretinography; Humans; Hydroxychloroquine; Prospective Studies; R | 2023 |
"En Face" Spectral-Domain Optical Coherence Tomography versus Multifocal Electroretinogram in Hydroxychloroquine Retinopathy Screening.
Topics: Chloroquine; Cohort Studies; Electroretinography; Humans; Hydroxychloroquine; Prospective Studies; R | 2023 |
"En Face" Spectral-Domain Optical Coherence Tomography versus Multifocal Electroretinogram in Hydroxychloroquine Retinopathy Screening.
Topics: Chloroquine; Cohort Studies; Electroretinography; Humans; Hydroxychloroquine; Prospective Studies; R | 2023 |
Retinal microvascular density analysis in patients with rheumatoid arthritis treated with hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Fluorescein Angiography; Humans; Hydroxychloroquine; Microvascular Density; R | 2023 |
Hydroxychloroquine retinopathy screening guidelines: a false positive.
Topics: Antirheumatic Agents; Artificial Intelligence; Fluorescein Angiography; Humans; Hydroxychloroquine; | 2023 |
Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus Erythematosus, Sys | 2023 |
Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study.
Topics: Antirheumatic Agents; Cohort Studies; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Ret | 2023 |
Summary for Patients: Hydroxychloroquine Dose and Risk for Incident Retinopathy.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases | 2023 |
Screening for toxic retinopathy due to antimalarial drugs in Tunisia.
Topics: Antimalarials; Cross-Sectional Studies; Humans; Hydroxychloroquine; Retinal Diseases; Tomography, Op | 2023 |
Mitigating Hydroxychloroquine Toxicity with a Clinical Decision Support Tool.
Topics: Antirheumatic Agents; Decision Support Systems, Clinical; Humans; Hydroxychloroquine; Retina; Retina | 2023 |
Nationwide patterns of hydroxychloroquine dosing and monitoring of retinal toxicity in patients with systemic lupus erythematosus.
Topics: Antirheumatic Agents; Body Weight; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retina | 2023 |
Practice Patterns of Screening for Hydroxychloroquine Retinopathy in South Korea.
Topics: Academies and Institutes; Cohort Studies; Female; Humans; Hydroxychloroquine; Middle Aged; Republic | 2023 |
Hydroxychloroquine and retinopathy risk.
Topics: Cohort Studies; Humans; Hydroxychloroquine; Retinal Diseases | 2023 |
Cone Density Distribution and Related Factors in Patients Receiving Hydroxychloroquine Treatment.
Topics: Adolescent; Aged; Eye Injuries; Humans; Hydroxychloroquine; Retina; Retinal Cone Photoreceptor Cells | 2023 |
The 2016 American Academy of Ophthalmology Hydroxychloroquine Dosing Guidelines For Short, Obese Patients.
Topics: Academies and Institutes; Adult; Aged; Antirheumatic Agents; Body Mass Index; Cross-Sectional Studie | 2019 |
Evaluation of Hydroxychloroquine Retinopathy Using Ultra-Widefield Fundus Autofluorescence: Peripheral Findings in the Retinopathy.
Topics: Adult; Aged; Antirheumatic Agents; Asian People; Female; Fluorescein Angiography; Humans; Hydroxychl | 2020 |
Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.
Topics: Adult; Age Factors; Antirheumatic Agents; Body Mass Index; Female; Humans; Hydroxychloroquine; Lupus | 2020 |
Hydroxychloroquine in diabetes and dyslipidaemia: primum non nocere.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Enzyme Inhibitors; Human | 2020 |
The 2016 American Academy of Ophthalmology Recommendations for Hydroxychloroquine Dosing Give Accurate Advice for All Patients.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Obesity; Ophthalmology; Retinal Diseases; United S | 2019 |
Reply.
Topics: Humans; Hydroxychloroquine; Retinal Diseases | 2020 |
Additional Analyses to Confirm Relationship of Hydroxychloroquine Blood Levels to Retinopathy: Comment on the Article by Petri et al.
Topics: Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; R | 2020 |
Structural Retinal Assessment Using Optical Coherence Tomography and Fundus Fluorescein Angiography in Systemic Lupus Erythematosus Patients.
Topics: Adult; Antirheumatic Agents; Correlation of Data; Early Diagnosis; Female; Fluorescein Angiography; | 2021 |
Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram in patients with rheumatic disorders.
Topics: Adult; Aged; Antirheumatic Agents; Electroretinography; Female; Fluorescein Angiography; Humans; Hyd | 2020 |
Hydroxychloroquine Ocular Toxicity: Lessons Learned.
Topics: Antirheumatic Agents; Female; Fundus Oculi; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2019 |
What every nephrologist needs to know about hydroxychloroquine toxicity
.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Kidney; Lupus Erythematosus, System | 2020 |
Ocular involvement in systemic lupus erythematosus patients: a paradigm shift based on the experience of a tertiary referral center.
Topics: Adult; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Female; | 2020 |
Hydroxychloroquine baseline retinopathy screening: when to refer patients? A practical approach to optimise resource use.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases; Visual Field Tests | 2020 |
Monitoring for hydroxychloroquine retinopathy.
Topics: Humans; Hydroxychloroquine; Retinal Diseases; Visual Field Tests | 2020 |
Keeping an Eye on Hydroxychloroquine Retinopathy.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases; Tomography, Optical Coherence; V | 2020 |
TOPOGRAPHIC OPTICAL COHERENCE TOMOGRAPHY SEGMENTATION SHOWS LIMITED ELLIPSOID ZONE RECOVERY IN MILD HYDROXYCHLOROQUINE RETINOPATHY.
Topics: Antirheumatic Agents; Cross-Sectional Studies; Fluorescein Angiography; Humans; Hydroxychloroquine; | 2022 |
Hydroxychloroquine-induced Retinal Toxicity.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases; Tomography, Optical Coherence | 2020 |
Genetic susceptibility to hydroxychloroquine retinal toxicity.
Topics: Adult; Aged; Antirheumatic Agents; Australia; Case-Control Studies; Female; Genetic Markers; Genetic | 2020 |
Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Hyperpigmen | 2020 |
Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.
Topics: Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytochrom | 2020 |
Hydroxychloroquine hitting the headlines-retinal considerations.
Topics: Antirheumatic Agents; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Retina; Retinal Diseases; | 2020 |
COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?
Topics: Antirheumatic Agents; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topi | 2020 |
Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.
Topics: Adult; Antirheumatic Agents; Case-Control Studies; Female; Humans; Hydroxychloroquine; Lupus Erythem | 2020 |
[Is there a need for ophthalmological surveillance in the case of short-term hydroxychloroquine treatment during this COVID-19 pandemic?]
Topics: Antimalarials; Betacoronavirus; Bone Density Conservation Agents; Contraindications, Drug; Coronavir | 2020 |
Comment on: How to set up a Hydroxychloroquine Retinopathy Screening Service.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases | 2021 |
Hydroxychloroquine retinopathy: screening and genetics.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases; Tomography, Optical Coherence; V | 2021 |
Use of OCT Retinal Thickness Deviation Map for Hydroxychloroquine Retinopathy Screening.
Topics: Adult; Aged; Antirheumatic Agents; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Male | 2021 |
Facts, not Fear: Safety of Hydroxychloroquine.
Topics: Acute Generalized Exanthematous Pustulosis; Agranulocytosis; Anemia, Aplastic; Antirheumatic Agents; | 2020 |
Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria.
Topics: Antirheumatic Agents; Fluorescein Angiography; Humans; Hydroxychloroquine; Ophthalmologists; Prevale | 2021 |
Two years' experience of screening for hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Electroretinography; Humans; Hydroxychloroquine; Prospective Studies; Retinal | 2021 |
Screening for Hydroxychloroquine Retinal Toxicity in Indian Patients.
Topics: Adult; Antirheumatic Agents; Cross-Sectional Studies; Humans; Hydroxychloroquine; Retinal Diseases; | 2021 |
Do Hydroxychloroquine Blood Levels and Dose Identify Different Populations at Risk of Retinopathy? Comment on the Article by Petri et al.
Topics: Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; R | 2020 |
Reply.
Topics: Hydroxychloroquine; Retinal Diseases | 2020 |
Is optical coherence tomography angiography a useful tool in the screening of hydroxychloroquine retinopathy?
Topics: Cross-Sectional Studies; Fluorescein Angiography; Humans; Hydroxychloroquine; Retinal Diseases; Reti | 2021 |
Early-Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels: Comment on the Article by Petri et al.
Topics: Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; R | 2021 |
An objective method of diagnosing hydroxychloroquine maculopathy.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Macular Degeneration; Male; Middle Aged; R | 2021 |
Reply.
Topics: Humans; Hydroxychloroquine; Retinal Diseases | 2021 |
Quantitative Fundus Autofluorescence in HCQ Retinopathy.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Child; Electroretinography; Female; Fluorescein Angio | 2020 |
Hydroxychloroquine retinopathy-less than meets the eye.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases; Tomography, Optical Coherence; V | 2021 |
Long-Term Progression of Pericentral Hydroxychloroquine Retinopathy.
Topics: Adult; Aged; Antirheumatic Agents; Disease Progression; Female; Follow-Up Studies; Humans; Hydroxych | 2021 |
Different Control Populations May Lead to Different Understanding of Hydroxychloroquine Blood Levels as a Risk Factor for Retinopathy: Comment on the Article by Petri et al.
Topics: Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; R | 2021 |
Comment on: Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Mass Screening; Retinal Diseases | 2021 |
Reply to Comment on: Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Mass Screening; Retinal Diseases | 2021 |
Hydroxychloroquine Retinal Toxicity and Its Association with Dosage.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases | 2021 |
Improving eye screening practice among pediatric rheumatology patients receiving hydroxychloroquine.
Topics: Adolescent; Antirheumatic Agents; Child; Female; Hospitals, Pediatric; Humans; Hydroxychloroquine; I | 2021 |
SEQUENTIAL RETINAL THICKNESS ANALYSIS SHOWS HYDROXYCHLOROQUINE DAMAGE BEFORE OTHER SCREENING TECHNIQUES.
Topics: Aged; Antirheumatic Agents; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Middle Aged | 2021 |
The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary.
Topics: Chloroquine; Humans; Hydroxychloroquine; Ophthalmologists; Retinal Diseases; United Kingdom | 2021 |
Non-central serous chorioretinopathy in a patient with systemic lupus erythematosus and hydroxychloroquine retinopathy.
Topics: Adrenal Cortex Hormones; Adult; Antirheumatic Agents; Disease Progression; Drug Therapy, Combination | 2021 |
Hydroxychloroquine screening in the UK-closing the gaps.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Ophthalmologists; Prevalence; Retinal Diseases; Un | 2021 |
American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity.
Topics: Antirheumatic Agents; Deprescriptions; Dermatology; Humans; Hydroxychloroquine; Mass Screening; Opht | 2021 |
Baseline retinal testing is no longer recommended for hydroxychloroquine users in the United Kingdom.
Topics: Humans; Hydroxychloroquine; Practice Guidelines as Topic; Retina; Retinal Diseases; Tomography, Opti | 2021 |
Accuracy of self-reported risk factors for hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases; Risk Factors; Self Report | 2022 |
Screening for hydroxychloroquine retinopathy in Australia.
Topics: Antirheumatic Agents; Australia; Drug-Related Side Effects and Adverse Reactions; Guidelines as Topi | 2021 |
Prevalence of hydroxychloroquine retinopathy with long-term use in a cohort of Indian patients with rheumatic diseases.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Cross-Sectional Studies; D | 2021 |
New recommendations for retinal monitoring in hydroxychloroquine users: baseline testing is no longer supported.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Tomography, Optical Cohe | 2021 |
Macula pigment optical densitometry changes in hydroxychloroquine use.
Topics: Adult; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Densitom | 2021 |
Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence.
Topics: Adult; Antirheumatic Agents; Europe; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, System | 2021 |
Ocular findings in Japanese patients with hydroxychloroquine retinopathy developing within 3 years of treatment.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Japan; Retinal Diseases; Retrospective Studies; To | 2021 |
More Steps Forward to Optimize the Dosing of Hydroxychloroquine: Comment on the Article by Petri et al.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases | 2021 |
Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report.
Topics: Adult; Anti-Inflammatory Agents; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lupus | 2021 |
A Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials.
Topics: Antimalarials; Dermatology; Humans; Hydroxychloroquine; Retinal Diseases; Tomography, Optical Cohere | 2021 |
ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa.
Topics: Adult; Aged; Aged, 80 and over; Diagnosis, Differential; Electroretinography; Enzyme Inhibitors; Fem | 2017 |
Antimalarial drug retinopathy: A typical « Bull's eyes » appearance of fundus.
Topics: Adult; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 2018 |
Hydroxychloroquine toxicity and aromatase inhibitors.
Topics: Anastrozole; Aromatase Inhibitors; Dermatologic Agents; Drug Synergism; Drug Therapy, Combination; F | 2017 |
The gathering storm: hydroxychloroquine retinopathy screening in the U.K.
Topics: Antirheumatic Agents; Early Diagnosis; Humans; Hydroxychloroquine; Retinal Diseases; United Kingdom; | 2017 |
Macular ganglion cell-inner plexiform layer thickness for detection of early retinal toxicity of hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Case-Control Studies; Cross-Sectional Studies; Female; Humans; Hy | 2018 |
The effect of oral acetazolamide on cystoid macular edema in hydroxychloroquine retinopathy: a case report.
Topics: Acetazolamide; Administration, Oral; Antirheumatic Agents; Carbonic Anhydrase Inhibitors; Dose-Respo | 2017 |
Hydroxychloroquine and the eye: an old unsolved problem.
Topics: Antirheumatic Agents; Electroretinography; Humans; Hydroxychloroquine; Retinal Diseases | 2017 |
Hydroxychloroquine use: the potential impact of new ocular screening guidelines.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Practice Guidelines as Topic; Retinal Diseases | 2018 |
Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Electroretinography; | 2017 |
Risk of Retinal Toxicity in Longterm Users of Hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroqu | 2017 |
Choroidal Thinning Associated With Hydroxychloroquine Retinopathy.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Choroid; Female; Humans; Hydro | 2017 |
Optical Coherence Tomography Protocols for Screening of Hydroxychloroquine Retinopathy in Asian Patients.
Topics: Adult; Aged; Antirheumatic Agents; Female; Follow-Up Studies; Fovea Centralis; Humans; Hydroxychloro | 2017 |
Perifoveal interdigitation zone loss in hydroxychloroquine toxicity leads to subclinical bull's eye lesion appearance on near-infrared reflectance imaging.
Topics: Antirheumatic Agents; Electroretinography; Fluorescein Angiography; Fovea Centralis; Humans; Hydroxy | 2018 |
Solving the Hydroxychloroquine Dosing Dilemma With a Smartphone App.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Hydroxychloroquine; Retinal Diseases; S | 2018 |
TOXIC EFFECTS OF HYDROXYCHLOROQUINE ON THE CHOROID: Evidence From Multimodal Imaging.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Choroid; Female; Fluorescein Angiography; | 2019 |
Multimodal imaging characteristics of hydroxychloroquine retinopathy.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Diagnosis, Differential; Female; Fluorescein Angiog | 2018 |
Response to risk of hydroxychloroquine retinopathy is not related to systemic lupus erythematosus or rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Electroretinography; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2018 |
Retinopathy from hydroxychloroquine is not related to lupus or rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; Humans; Hydroxychloroquine; Retina | 2018 |
Early macular toxicity following 2 months of hydroxychloroquine therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Macula Lutea; Metho | 2018 |
Requirement for retinal screening in patients taking hydroxychloroquine and chloroquine.
Topics: Adolescent; Antirheumatic Agents; Chloroquine; Humans; Hydroxychloroquine; Mass Screening; Retinal D | 2018 |
Macular sensitivities measured by microperimetry in patients on hydroxychloroquine treatment.
Topics: Adult; Antirheumatic Agents; Autoimmune Diseases; Case-Control Studies; Female; Humans; Hydroxychlor | 2018 |
[Antimalarial drug retinopathy].
Topics: Adult; Antimalarials; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; Lupus Erythemato | 2018 |
Monitoring for retinal toxicity in patients taking hydroxychloroquine and chloroquine.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Mass Screening; Practice Guidelines as Topic | 2019 |
Comparison between multifocal ERG and C-Scan SD-OCT ("en face" OCT) in patients with a suspicion of antimalarial retinal toxicity: preliminary results.
Topics: Adult; Aged; Antimalarials; Electroretinography; Female; Fundus Oculi; Humans; Hydroxychloroquine; M | 2018 |
Hydroxychloroquine-induced retinal toxicity in an asymptomatic patient.
Topics: Aged; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Scleroderm | 2018 |
Optical Coherence Tomography Minimum Intensity as an Objective Measure for the Detection of Hydroxychloroquine Toxicity.
Topics: Adult; Aged; Antirheumatic Agents; Case-Control Studies; Electroretinography; Female; Humans; Hydrox | 2018 |
[Variability of chloroquine and hydroxychloroquine retinopathy among various ethnicities].
Topics: Antirheumatic Agents; Asian People; Chloroquine; Delayed Diagnosis; Early Diagnosis; Electroretinogr | 2018 |
Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016.
Topics: Antirheumatic Agents; Drug Dosage Calculations; Female; Guideline Adherence; Humans; Hydroxychloroqu | 2018 |
Effect of topical dorzolamide therapy on cystoid macular edema in hydroxychloroquine retinopathy.
Topics: Administration, Topical; Adult; Aged; Antirheumatic Agents; Carbonic Anhydrase Inhibitors; Female; F | 2018 |
Case Report: Hydroxychloroquine Retinopathy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; Female; Fluorescein Angiography; H | 2018 |
Using hydroxychloroquine and protecting the retina.
Topics: Antirheumatic Agents; Autoimmune Diseases; Electroretinography; Humans; Hydroxychloroquine; Retinal | 2018 |
Evidence for the Detection of Subclinical Retinal Involvement in Systemic Lupus Erythematosus and Sjögren Syndrome: A Potential Association with Therapies.
Topics: Antirheumatic Agents; Case-Control Studies; Female; Humans; Hydroxychloroquine; Immunosuppressive Ag | 2018 |
Comment on: Hydroxychloroquine-induced retinal toxicity in an asymptomatic patient.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retina; Retinal Diseases | 2018 |
ASYMMETRIC HYDROXYCHLOROQUINE MACULAR TOXICITY WITH APHAKIC FELLOW EYE.
Topics: Antirheumatic Agents; Aphakia, Postcataract; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroqui | 2021 |
Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.
Topics: Adult; Aged; Antirheumatic Agents; Body Mass Index; Body Weight; Drug Dosage Calculations; Female; H | 2018 |
Hydroxychloroquine: an update.
Topics: Humans; Hydroxychloroquine; Newspapers as Topic; Retinal Diseases | 2018 |
Clinical display of mfERG data.
Topics: Antirheumatic Agents; Data Display; Electroretinography; Female; Fundus Oculi; Humans; Hydroxychloro | 2018 |
Comment on: Hydroxychloroquine-induced retinal toxicity in an asymptomatic patient: reply.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retina; Retinal Diseases | 2018 |
Bilateral Severe Decreased Vision With Normal Examination Findings.
Topics: Adult; Antibiotics, Antineoplastic; Antirheumatic Agents; Autoimmune Diseases; Cataract; Cystic Fibr | 2018 |
Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Eye | 2018 |
Evaluation of Retromode Imaging for Use in Hydroxychloroquine Retinopathy.
Topics: Adult; Aged; Analysis of Variance; Antirheumatic Agents; Case-Control Studies; Female; Humans; Hydro | 2018 |
Early morpho-functional changes in patients treated with hydroxychloroquine: a prospective cohort study.
Topics: Antirheumatic Agents; Cohort Studies; Electroretinography; Female; Humans; Hydroxychloroquine; Male; | 2018 |
Optical coherence tomography angiography for screening of hydroxychloroquine-induced retinal alterations.
Topics: Antirheumatic Agents; Choroid; Early Diagnosis; Female; Fluorescein Angiography; Humans; Hydroxychlo | 2018 |
Quantitative assessment of outer retinal layers and ellipsoid zone mapping in hydroxychloroquine retinopathy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Antirheumatic Agents; Case-Control Studie | 2019 |
The optical coherence tomography angiography findings of rheumatoid arthritis patients taking hydroxychloroquine.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Female; Fluorescein Angiog | 2019 |
MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study.
Topics: Adult; Aged; Antirheumatic Agents; Enzyme Inhibitors; Female; Fluorescein Angiography; Humans; Hydro | 2019 |
Real-world database examining the association between hydroxychloroquine and retinopathy in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Databases, Factual; Female; Follow-Up Studies; Humans; Hydroxychloro | 2019 |
[Spectral Domain Optical Coherence Tomographic Findings in Systemic Lupus erythematosus in Patients Treated with Chloroquine].
Topics: Chloroquine; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Ret | 2019 |
The Validity of Optical Coherence Tomography Angiography as a Screening Test for the Early Detection of Retinal Changes in Patients with Hydroxychloroquine Therapy.
Topics: Adult; Aged; Antirheumatic Agents; Cross-Sectional Studies; Female; Fluorescein Angiography; Fovea C | 2019 |
En Face Optical Coherence Tomography Imaging of the Photoreceptor Layers in Hydroxychloroquine Retinopathy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Fluorescein Angiography; Humans; H | 2019 |
Hydroxychloroquine-induced retinal toxicity in systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Eryt | 2018 |
Night Blindness, Ring Scotoma, and a Nonrecordable Electroretinogram in an Elderly Woman.
Topics: Aged; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxychloroquine; Night Blindness | 2019 |
SEQUENTIAL CHANGES IN HYDROXYCHLOROQUINE RETINOPATHY UP TO 20 YEARS AFTER STOPPING THE DRUG: Implications for Mild Versus Severe Toxicity.
Topics: Antirheumatic Agents; Disease Progression; Enzyme Inhibitors; Female; Fluorescein Angiography; Fovea | 2019 |
Screening for Hydroxychloroquine Retinopathy-Can We Do Better?
Topics: Fluorescein Angiography; Humans; Hydroxychloroquine; Retinal Diseases; Visual Field Tests | 2019 |
Structural and Functional Characterization of the Retinal Effects of Hydroxychloroquine Treatment in Healthy Eyes.
Topics: Antirheumatic Agents; Cross-Sectional Studies; Female; Fovea Centralis; Humans; Hydroxychloroquine; | 2019 |
Macular toxicity after short-term hydroxychloroquine therapy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; Female; Fluorescein Angiogr | 2019 |
Hydroxychloroquine: do we all see eye to eye? A single-site analysis of hydroxychloroquine dosing compared with the 2016 Revision of the American Academy of Ophthalmology guidelines.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Practice Guidelines | 2019 |
LONGITUDINAL CHANGES IN EYES WITH HYDROXYCHLOROQUINE RETINAL TOXICITY.
Topics: Adult; Aged; Antirheumatic Agents; Enzyme Inhibitors; Female; Fluorescein Angiography; Humans; Hydro | 2019 |
Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Antirheumatic Agents; Cohort Studies; Female; Follow-Up Studies; Hospitals, University; | 2019 |
Early hydroxychloroquine retinopathy: optical coherence tomography abnormalities preceding Humphrey visual field defects.
Topics: Adult; Aged; Antirheumatic Agents; Chronic Disease; Early Diagnosis; Electroretinography; Female; Hu | 2019 |
Evaluation of photoreceptor outer segment length in hydroxychloroquine users.
Topics: Antirheumatic Agents; Female; Follow-Up Studies; Fovea Centralis; Humans; Hydroxychloroquine; Male; | 2019 |
Current screening practice in patients under long-term hydroxychloroquine medication in Taiwan: A nationwide population-based cohort study.
Topics: Adult; Aged; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxychloroquine; Logistic | 2019 |
[The flying saucer sign in toxic hydroxychloroquine retinopathy].
Topics: Female; Fundus Oculi; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Middle Aged; Multim | 2019 |
Hydroxychloroquine Retinopathy: Drug Cessation versus Drug Continuation.
Topics: Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Middle Aged; Retinal Diseases; Withholdin | 2019 |
Hydroxychloroquine Retinal Toxicity.
Topics: Antirheumatic Agents; Color Vision Defects; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2019 |
How to set up a Hydroxychloroquine Retinopathy Screening Service.
Topics: Adult; Antirheumatic Agents; Child; Diagnostic Imaging; Humans; Hydroxychloroquine; Mass Screening; | 2019 |
The Diagnostic Utility of Multifocal Electroretinography in Detecting Chloroquine and Hydroxychloroquine Retinal Toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Electroretinography; Female; Fluo | 2019 |
Fluorescence Lifetimes in Patients With Hydroxychloroquine Retinopathy.
Topics: Adult; Aged; Antirheumatic Agents; Case-Control Studies; Electroretinography; Female; Fluorescein An | 2019 |
Evaluation of Maculopathy in Patients Using Hydroxychloroquine
Topics: Adult; Aged; Antirheumatic Agents; Connective Tissue Diseases; Female; Fluorescein Angiography; Foll | 2019 |
Imaging of Hydroxychloroquine Toxicity with Fluorescence Lifetime Imaging Ophthalmoscopy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Cross-Sectional Studies; Female; F | 2019 |
Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Cohort Studies; Enzyme Inhibitors; Female; Humans; H | 2013 |
Fundus autofluorescence in hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Female; Fundus Oculi; Humans; Hydroxychloroquine; Middle Aged; Optical Imaging | 2013 |
Screening for hydroxychloroquine toxicity in children.
Topics: Antirheumatic Agents; Child; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Re | 2013 |
Value of red targets and pattern deviation plots in visual field screening for hydroxychloroquine retinopathy.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxych | 2013 |
Microperimetric sensitivity in patients on hydroxychloroquine (Plaquenil) therapy.
Topics: Adult; Aged; Analysis of Variance; Antirheumatic Agents; Cohort Studies; Connective Tissue Diseases; | 2013 |
Reply: To PMID 23218706.
Topics: Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Female; Humans; Hydroxychloroquine; M | 2013 |
Impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice.
Topics: Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Female; Humans; Hydroxychloroquine; M | 2013 |
Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Fluorescein A | 2013 |
Blurred vision: targeting a diagnosis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Early Diagnosis; Female; Hum | 2013 |
Fundus autofluorescence is not the best early screen for hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Optical Imaging; Retinal Diseases | 2013 |
Fundus autofluorescence is not the best early screen for hydroxychloroquine toxicity--reply.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Optical Imaging; Retinal Diseases | 2013 |
Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy.
Topics: Aged; Antirheumatic Agents; Electroretinography; Female; Fluorescein Angiography; Humans; Hydroxychl | 2014 |
RE: Microperimetry and the diagnosis of antimalarial maculopathy.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Retina; Retinal Disease | 2014 |
RE: Author reply:.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Retina; Retinal Disease | 2014 |
Effect of disease stage on progression of hydroxychloroquine retinopathy.
Topics: Aged; Antirheumatic Agents; Disease Progression; Female; Fluorescein Angiography; Humans; Hydroxychl | 2014 |
Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users.
Topics: Aged; Ambulatory Care; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Color Perception Te | 2014 |
Validation of the colour difference plot scoring system analysis of the 103 hexagon multifocal electroretinogram in the evaluation of hydroxychloroquine retinal toxicity.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; False Pos | 2014 |
Retinal toxicity found in a patient with systemic lupus erythematosus prior to 5 years of treatment with hydroxychloroquine.
Topics: Antirheumatic Agents; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Hydroxychlor | 2014 |
Pericentral retinopathy and racial differences in hydroxychloroquine toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Asian People; Databases, Factual; Electroretin | 2015 |
A subtle case of hydroxychloroquine retinopathy: spectral domain optical coherence tomography findings.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Female; Humans; Hydroxychloroquine; Middle Aged; Retina; | 2014 |
We need to be better prepared for hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Male; Retina; Retinal Diseases | 2014 |
The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.
Topics: Adult; Aged; Antirheumatic Agents; Body Weight; Case-Control Studies; Electroretinography; Female; F | 2014 |
Hydroxychloroquine retinopathy after short-term therapy.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Middle Aged; Retinal Diseases; Vision Diso | 2014 |
Macular retinal ganglion cell-inner plexiform layer thickness in patients on hydroxychloroquine therapy.
Topics: Adult; Antirheumatic Agents; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Nerve Fibe | 2014 |
[SD-OCT As screening test for hydroxychloroquine retinopathy: The «flying saucer» sign].
Topics: Adolescent; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Fluorescein Angiography; Fovea Cent | 2015 |
Subjective and objective screening tests for hydroxychloroquine toxicity.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Diagnostic Technique | 2015 |
A comparison of structural and functional changes in patients screened for hydroxychloroquine retinopathy.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxychloroqui | 2015 |
Spectral-domain optical coherence tomography in hydroxychloroquine retinopathy.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Humans; Hydroxychloroquine; Middle Aged; Retin | 2015 |
Prevention of hydroxychloroquine-related retinal toxic effects.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Male; Multimodal Imaging; Retina; Retinal | 2015 |
Prevention of hydroxychloroquine-related retinal toxic effects--reply.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Male; Multimodal Imaging; Retina; Retinal | 2015 |
Hydroxychloroquine and the retina.
Topics: Ambulatory Care; Antirheumatic Agents; Chloroquine; Diagnostic Techniques, Ophthalmological; Female; | 2015 |
Pericentral hydroxychloroquine retinopathy in Korean patients.
Topics: Adult; Aged; Antirheumatic Agents; Asian People; Disease Progression; Female; Fluorescein Angiograph | 2015 |
Multimodal imaging in a severe case of hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Atrophy; Electroretinography; Female; Fluorescein Angiography; Humans; Hydroxy | 2015 |
[Clinical evaluation of the new screening procedures for hydroxychloroquine retinopathy, according to the American Academy of Ophthalmology guidelines. Prospective study of 184 patients].
Topics: Aged; Aged, 80 and over; Diagnostic Techniques, Ophthalmological; Female; Humans; Hydroxychloroquine | 2015 |
Assessment of parafoveal cone density in patients taking hydroxychloroquine in the absence of clinically documented retinal toxicity.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Count; Electroretinography; Female; Fovea C | 2015 |
Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral fovea.
Topics: Adult; Aged; Antimalarials; Antirheumatic Agents; Female; Fovea Centralis; Humans; Hydroxychloroquin | 2015 |
Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study.
Topics: Electroretinography; Female; Functional Laterality; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2015 |
Hydroxychloroquine screening practice patterns within a large multispecialty ophthalmic practice.
Topics: Academies and Institutes; Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Child; E | 2015 |
Volumetric ellipsoid zone mapping for enhanced visualisation of outer retinal integrity with optical coherence tomography.
Topics: Algorithms; Antirheumatic Agents; Basement Membrane; Epiretinal Membrane; Fibrinolysin; Fibrinolytic | 2016 |
Recessive Stargardt disease phenocopying hydroxychloroquine retinopathy.
Topics: Adult; Antimalarials; ATP-Binding Cassette Transporters; Child; Electroretinography; Female; Genes, | 2016 |
Detection of Hydroxychloroquine Retinal Toxicity by Automated Perimetry in 60 Rheumatoid Arthritis Patients with Normal Fundoscopic Findings.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Female; Humans; Hydroxy | 2015 |
Evaluation of a follow-up protocol for patients on chloroquine and hydroxychloroquine treatment.
Topics: Antirheumatic Agents; Chloroquine; Electroretinography; Female; Fluorescein Angiography; Follow-Up S | 2016 |
[Multimodal imaging of hydroxychloroquine and chloroquine retinopathy].
Topics: Adult; Atrophy; Chloroquine; Diagnostic Techniques, Ophthalmological; Drug Substitution; Female; Hum | 2016 |
Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.
Topics: Adult; Aged; Antimalarials; Chronic Disease; Color Vision Defects; Electroretinography; Female; Graf | 2015 |
Diagnostic and Therapeutic Challenges.
Topics: Antirheumatic Agents; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Erythematos | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity.
Topics: Adult; Antimalarials; Biological Transport; Drug Monitoring; Drug-Related Side Effects and Adverse R | 2016 |
Hydroxychloroquine-Induced Retinal Toxicity.
Topics: Antirheumatic Agents; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Lupus Erythematos | 2016 |
The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both.
Topics: Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Drug-Related Side Effects and Adverse | 2016 |
Retinopathy in the Era of Routine Hydroxychloroquine Monitoring.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases | 2016 |
VOLUMETRIC SINGLE-LAYER INNER RETINAL ANALYSIS IN PATIENTS WITH HYDROXYCHLOROQUINE TOXICITY.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antimalarials; Antirheumatic Agents; Female; | 2016 |
Update on Screening Recommendations for Hydroxychloroquine Retinopathy.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases | 2016 |
The Demise of the Bull's Eye (Screening for Hydroxychloroquine Retinopathy).
Topics: Antimalarials; Antirheumatic Agents; Electroretinography; Humans; Hydroxychloroquine; Retina; Retina | 2016 |
Implementation of recommendations for the screening of hydroxychloroquine retinopathy: poor adherence of rheumatologists and ophthalmologists.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Guideline Adherence; Humans; Hydroxychloroquine; Israel | 2017 |
AIMING FOR THE BULL'S EYE: The Cost-Utility of Screening for Hydroxychloroquine Retinopathy.
Topics: Academies and Institutes; Antimalarials; Antirheumatic Agents; Cost-Benefit Analysis; Diagnostic Tec | 2016 |
Impact of an Electronic Decision Support Tool on Hydroxychloroquine Screening.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Child; Decision Support Techniques | 2016 |
The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Ophthalmologists; Prevalence; Retinal Diseases | 2016 |
Adaptive optics: a tool for screening hydroxychloroquine-induced maculopathy?
Topics: Antirheumatic Agents; Electroretinography; Humans; Hydroxychloroquine; Retinal Diseases | 2017 |
Hydroxychloroquine prescribing and monitoring practices among Irish dermatologists and rheumatologists.
Topics: Antirheumatic Agents; Dermatologists; Early Diagnosis; Humans; Hydroxychloroquine; Ireland; Ophthalm | 2017 |
Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic Diseases.
Topics: Adult; Aged; Antirheumatic Agents; Asian People; Drug Dosage Calculations; Female; Fluorescein Angio | 2017 |
Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System.
Topics: Antirheumatic Agents; Delivery of Health Care, Integrated; Dose-Response Relationship, Drug; Electro | 2017 |
Hydroxychloroquine retinopathy: an emerging problem.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Early Diagnosis; Electroretinography; Fema | 2017 |
Hydroxychloroquine Screening Alert: Change is in the Wind.
Topics: Antirheumatic Agents; Dose-Response Relationship, Drug; Electroretinography; Fluorescein Angiography | 2017 |
Re: Marmor et al.: American Academy of Ophthalmology Statement: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). (Ophthalmology 2016;123:1386-1394).
Topics: Antirheumatic Agents; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; Ophthalmology; R | 2017 |
Chloroquine Retinopathy under Inadequately Weight Adjusted Dosage: Early Detection by Multimodal Imaging.
Topics: Humans; Hydroxychloroquine; Multimodal Imaging; Retinal Diseases | 2017 |
Value of Microperimetry in Detecting Early Retinal Toxicity of Hydroxychloroquine in Children with Juvenile Systemic Lupus Erythematosus.
Topics: Adolescent; Antirheumatic Agents; Child; Cross-Sectional Studies; Early Diagnosis; Electroretinograp | 2017 |
Hydroxychloroquine retinopathy screening.
Topics: Adult; Aged; Antirheumatic Agents; Clinical Competence; Cost-Benefit Analysis; Female; Health Care S | 2008 |
Progressive hydroxychloroquine toxicity mimicking low-tension glaucoma after discontinuation of the drug.
Topics: Aged; Atrophy; Diagnosis, Differential; Disease Progression; Drug Administration Schedule; Electrore | 2010 |
[Antimalarial's retinopaty remains a current threat].
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Cohort Studies; Dose-Response Relationship, Drug; | 2009 |
Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Opht | 2009 |
Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Enzyme Inhibitors; Female; Humans; Hydroxychloroquin | 2010 |
Preferential Hyperacuity Perimetry to detect hydroxychloroquine retinal toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis; Female; Humans; Hydroxychloroquine; | 2009 |
Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss.
Topics: Antirheumatic Agents; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Erythematos | 2009 |
Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity.
Topics: Adult; Aged; Antimalarials; Antirheumatic Agents; Chronic Disease; Female; Humans; Hydroxychloroquin | 2010 |
Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up.
Topics: Antirheumatic Agents; Contrast Sensitivity; Disease Progression; Electroretinography; Female; Fluore | 2010 |
Hydroxychloroquine retinopathy: screening needed to prevent blindness.
Topics: Adult; Antirheumatic Agents; Blindness; Female; Humans; Hydroxychloroquine; Retinal Diseases | 2010 |
Retina in rheumatic diseases: standard full field and multifocal electroretinography in hydroxychloroquine retinal dysfunction.
Topics: Adult; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxychloroquine; Male; Middle A | 2011 |
Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Follow-Up Studies; Humans; Hydroxy | 2010 |
Clinical characteristics of hydroxychloroquine retinopathy.
Topics: Aged; Antirheumatic Agents; Color Vision; Female; Fluorescein Angiography; Humans; Hydroxychloroquin | 2011 |
Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study.
Topics: Adolescent; Adult; Aged; Antimalarials; Arthritis, Rheumatoid; Chi-Square Distribution; Chloroquine; | 2010 |
[The ERG contribution in early diagnosis of chloroquine and hydroxychloroquine maculopathy].
Topics: Antimalarials; Antirheumatic Agents; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; M | 2010 |
Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Dose-Response Relatio | 2010 |
Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Disease Progression; Drug Therapy | 2011 |
Retinal functional changes measured by frequency-doubling technology in patients treated with hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Case-Control Studies; Contrast Sensitivity | 2011 |
Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.
Topics: Academies and Institutes; Age Factors; Antirheumatic Agents; Chloroquine; Diagnostic Techniques, Oph | 2011 |
Hydroxychloroquine retinopathy: screening needed to prevent blindness.
Topics: Antirheumatic Agents; Blindness; Humans; Hydroxychloroquine; Practice Guidelines as Topic; Retinal D | 2011 |
[Multifocal electroretinography in follow-up of patients treated with hydroxychloroquine].
Topics: Electroretinography; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Middle Aged; Retin | 2011 |
Amsler grids for chloroquine toxicity.
Topics: Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Retina; R | 2011 |
Hydroxychloroquine: lean body weight dosing.
Topics: Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Retina; R | 2011 |
Hydroxychloroquine retinopathy combined with retinal pigment epithelium detachment.
Topics: Adult; Anti-Inflammatory Agents; Female; Humans; Hydroxychloroquine; Retinal Detachment; Retinal Dis | 2012 |
Chloroquine and hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Vis | 2011 |
[Critical review of the new recommendations on screening for hydroxychloroquine retinopathy].
Topics: Drug Monitoring; Humans; Hydroxychloroquine; Practice Guidelines as Topic; Retinal Diseases | 2012 |
Humphrey visual field findings in hydroxychloroquine toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Female; Humans; Hydroxychloroquine; Male; Middle Aged | 2011 |
Comparison of screening procedures in hydroxychloroquine toxicity.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnostic Techniques, Ophthalmological; E | 2012 |
Screening for hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Retina; R | 2012 |
Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Color Perception Tests; Diagnostic Techniques, Ophth | 2012 |
Quantitative assessment of the 103-hexagon multifocal electroretinogram in detection of hydroxychloroquine retinal toxicity.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Area Under Curve; Child; Cross-Sectional Studies; Ele | 2012 |
Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice.
Topics: Academies and Institutes; Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthriti | 2013 |
New trends in early diagnosis of hydroxychloroquine toxic retinopathy.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Early | 2012 |
Efficient and effective screening for hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Diagnostic Techniques, Ophthalmological; Female; Humans; Hydroxychloroquine; M | 2013 |
Screening for hydroxychloroquine toxicity by Texas ophthalmologists.
Topics: Antirheumatic Agents; Data Collection; Diagnostic Techniques, Ophthalmological; Drug Monitoring; Hum | 2002 |
Dosage of hydroxychloroquine should be based on ideal body weight: comment on the letter by Alarcón.
Topics: Adult; Antimalarials; Body Height; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; D | 2003 |
New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy.
Topics: Academies and Institutes; Antirheumatic Agents; Chloroquine; Diagnostic Techniques, Ophthalmological | 2003 |
The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Stud | 2003 |
Adherence to ophthalmologic monitoring for antimalarial toxicity in a lupus cohort.
Topics: Adult; Antimalarials; Antirheumatic Agents; Chloroquine; Cohort Studies; Drug Monitoring; Female; Gu | 2003 |
Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxychloroquine; Male; Mi | 2003 |
Chloroquine-induced retinal toxicity.
Topics: Antimalarials; Blindness; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Retinal Diseases; S | 2004 |
Assessing hydroxychloroquine toxicity by the multifocal ERG.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Electrooculography; Electroretinography; Humans; | 2004 |
ERG findings in patients using hydroxychloroquine.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxychloroqui | 2004 |
Ophthalmologic monitoring for antimalarial toxicity.
Topics: Antimalarials; Arthritis, Rheumatoid; Drug Monitoring; Greece; Humans; Hydroxychloroquine; Lupus Ery | 2004 |
Multifocal electroretinographic evaluation of long-term hydroxychloroquine users.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Color Perception Tests; Dermatologic Agent | 2004 |
Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al.
Topics: Autoimmune Diseases; Breast Feeding; Child, Preschool; Electroretinography; Female; Humans; Hydroxyc | 2004 |
Chloroquine-induced retinal toxicity.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases | 2005 |
Hydroxychloroquine screening.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases; Scotoma; Vision Screening | 2005 |
Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy.
Topics: Adult; Aged; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Di | 2005 |
[Ophthalmologic prevention of chloroquine and hydroxychloroquine induced retinopathy].
Topics: Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Diseases; | 2005 |
Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; Female; Humans; Hydroxychlo | 2005 |
The dilemma of hydroxychloroquine screening: new information from the multifocal ERG.
Topics: Antirheumatic Agents; Disease Progression; Electroretinography; Humans; Hydroxychloroquine; Retina; | 2005 |
Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy.
Topics: Adult; Aged; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional | 2006 |
Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Diagnostic Imaging; Electroretinography; Female; Flu | 2006 |
Reply to abnormalities on the multifocal electroretinogram may precede clinical signs of hydroxychloroquine retinotoxicity.
Topics: Antirheumatic Agents; Drug Administration Schedule; Electroretinography; Humans; Hydroxychloroquine; | 2007 |
[Severe chloroquine- and hydroxychloroquine-induced retinopathy].
Topics: Aged; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Dis | 2006 |
Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Child; Cros | 2007 |
High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; Fe | 2007 |
[Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses].
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Azathioprine; Child; Chloroquine; Dose-Response Relat | 2007 |
Retinal toxicity secondary to Plaquenil therapy.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnosis, Differential; Female; Follow-Up Studie | 2008 |
Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Inflammation; Informed Consent; Lupu | 2007 |
Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review : Review of mfERG ring ratios in Plaquenil toxicity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Autoimmune Diseases; Child; Dose-R | 2009 |
[Routine monitoring of patients treated with synthetic antimalarials].
Topics: Aged; Chloroquine; Color Perception Tests; Electroretinography; Female; Fluorescein Angiography; Fun | 1983 |
Static perimetry in chloroquine retinopathy. Perifoveal patterns of visual field depression.
Topics: Adult; Arthritis, Rheumatoid; Chloroquine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 1984 |
Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy.
Topics: Adult; Arthritis, Rheumatoid; Child; Chloroquine; Ciliary Body; Cornea; Drug Administration Schedule | 1983 |
Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment.
Topics: Adult; Aged; Arthritis, Rheumatoid; Drug Evaluation; Humans; Hydroxychloroquine; Middle Aged; Ophtha | 1983 |
Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials.
Topics: Arthritis, Rheumatoid; Body Weight; Chloroquine; Drug Administration Schedule; Humans; Hydroxychloro | 1983 |
Assessment of the retinal toxicity of hydroxychloroquine.
Topics: Adult; Age Factors; Aged; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Macu | 1981 |
Hydroxychloroquine. Seven-year experience.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Disea | 1982 |
Corticosteroid-sparing strategies in the treatment of retinal vasculitis in systemic lupus erythematosus.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Cohort Studies; Drug Therapy, Combination; Female; Foll | 1995 |
Ocular toxicity of antimalarials in dermatology: a survey of current practice.
Topics: Antimalarials; Dermatology; Drug Administration Schedule; Humans; Hydroxychloroquine; Quinacrine; Re | 1994 |
Hydroxychloroquine.
Topics: Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Monitoring, Physiologic; Retinal Disease | 1993 |
The ocular safety of hydroxychloroquine.
Topics: Female; Humans; Hydroxychloroquine; Incidence; Male; Prognosis; Prospective Studies; Retinal Disease | 1993 |
Hydroxychloroquine toxicity despite normal dose therapy.
Topics: Aged; Arthritis, Rheumatoid; Female; Fluorescein Angiography; Fundus Oculi; Humans; Hydroxychloroqui | 1993 |
Screening for antimalarial toxicity.
Topics: Chloroquine; Color Perception Tests; Corneal Diseases; Humans; Hydroxychloroquine; Retinal Diseases; | 1993 |
Hydroxychloroquine and visual screening in a rheumatology outpatient clinic.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Child; Cornea; Drug Administration | 1997 |
Should patients on hydroxychloroquine have their eyes examined regularly?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Corneal Diseases; Diagnostic Tests, Routine; Dose-Respo | 1997 |
Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice.
Topics: Adult; Aged; Antimalarials; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; In | 1997 |
[The therapy of systemic lupus erythematosus].
Topics: Antirheumatic Agents; Chloroquine; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retina | 1997 |
Hydroxychloroquine and retinal safety.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases; Risk Factors | 1998 |
Hydroxychloroquine retinopathy: is screening necessary?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Mass Screening; Retinal Dis | 1998 |
Current concepts in monitoring patients on antimalarials.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Monitoring, Physiologic; Practice Guidelines | 1998 |
Antimalarial drugs in the treatment of rheumatological diseases.
Topics: Aged; Antimalarials; Antirheumatic Agents; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Rhe | 1998 |
Screening for hydroxychloroquine retinopathy. Screening should be selective.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Retinal Diseases | 1998 |
Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Topics: Adult; Antimalarials; Antirheumatic Agents; Cohort Studies; Drug-Related Side Effects and Adverse Re | 1999 |
An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Dose-Response Relationship, Drug; Female; | 1999 |
Hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Electroretinography; Female; Fluorescein Angiography; H | 1999 |
Retinopathy after long term, standard doses of hydroxychloroquine.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Middle Aged; Retinal Diseases | 1999 |
Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series.
Topics: Aged; Antirheumatic Agents; Color Perception; Female; Humans; Hydroxychloroquine; Middle Aged; Ophth | 2000 |
Hydroxychloroquine retinopathy.
Topics: Antimalarials; Humans; Hydroxychloroquine; Retina; Retinal Diseases | 2001 |
Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease?
Topics: Aged; Aminoquinolines; ATP-Binding Cassette Transporters; Chloroquine; Genetic Predisposition to Dis | 2001 |
Rheumatologists' attitudes toward routine screening for hydroxychloroquine retinopathy.
Topics: Antirheumatic Agents; Attitude of Health Personnel; Female; Humans; Hydroxychloroquine; Liability, L | 2001 |
Progression of hydroxychloroquine retinopathy after discontinuation of therapy: case report.
Topics: Adult; Antimalarials; Female; Humans; Hydroxychloroquine; Retinal Diseases | 2001 |
Hydroxychloroquine retinopathy.
Topics: Antimalarials; Diagnostic Techniques, Ophthalmological; Humans; Hydroxychloroquine; Retina; Retinal | 2001 |
How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy?
Topics: Adult; Antimalarials; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Retinal Dis | 2002 |
Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity.
Topics: Aged; Antirheumatic Agents; Chloroquine; Dermatologic Agents; Drug-Related Side Effects and Adverse | 2002 |
Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology.
Topics: Academies and Institutes; Antirheumatic Agents; Chloroquine; Diagnostic Techniques, Ophthalmological | 2002 |
Long-term course of chloroquine retinopathy after cessation of medication.
Topics: Adult; Aged; Chloroquine; Color Perception Tests; Female; Fluorescein Angiography; Follow-Up Studies | 1979 |
Ocular manifestations of juvenile rheumatoid arthritis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Arthritis, Juvenile; Atropine; Cataract; Ch | 1975 |
Long-term course of antimalarial maculopathy after cessation of treatment.
Topics: Chloroquine; Follow-Up Studies; Humans; Hydroxychloroquine; Longitudinal Studies; Macula Lutea; Mala | 1992 |
Chloroquine retinopathy.
Topics: Chloroquine; Color Perception; Humans; Hydroxychloroquine; Retinal Diseases; Vision Tests; Visual Ac | 1991 |
Hydroxychloroquine retinopathy.
Topics: Electroretinography; Female; Fluorescein Angiography; Fundus Oculi; Humans; Hydroxychloroquine; Lupu | 1991 |
Is corneal deposition of antimalarial any indication of retinal toxicity?
Topics: Adult; Aged; Chloroquine; Cornea; Drug Overdose; Female; Fluorescein Angiography; Fundus Oculi; Huma | 1990 |
Screening for hydroxychloroquine retinal toxicity: is it necessary?
Topics: Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Male; Prospective Studies; Retina; Retina | 1990 |
Retinal damage due to antimalarial treatment.
Topics: Drug Administration Schedule; Humans; Hydroxychloroquine; Retinal Diseases | 1990 |
[C-wave changes in macular diseases].
Topics: Adolescent; Adult; Aged; Aging; Child; Electroretinography; Humans; Hydroxychloroquine; Macula Lutea | 1989 |
The blood-retinal barrier in chloroquine retinopathy.
Topics: Aged; Blood-Retinal Barrier; Chloroquine; Female; Fluorescein Angiography; Fluorometry; Humans; Hydr | 1989 |
Hydroxychloroquine sulfate and retinopathy.
Topics: Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Retinal Diseases | 1988 |
Ocular effects and safety of antimalarial agents.
Topics: Antimalarials; Chloroquine; Corneal Diseases; Drug Administration Schedule; Electrooculography; Elec | 1988 |
[The visual system in 30 subjects with discoid lupus erythematosus treated with hydroxychloroquine].
Topics: Adult; Electroretinography; Humans; Hydroxychloroquine; Lupus Erythematosus, Discoid; Middle Aged; R | 1988 |
Dose relationships in patients with early chloroquine retinopathy.
Topics: Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Retinal Dis | 1987 |
VEP pattern after photostress: an index of macular function.
Topics: Adult; Aged; Carotid Artery Diseases; Evoked Potentials, Visual; Humans; Hydroxychloroquine; Macula | 1987 |
The sensitivity of Amsler grid testing in early chloroquine retinopathy.
Topics: Adult; Chloroquine; Humans; Hydroxychloroquine; Retinal Diseases; Scotoma; Vision Tests | 1985 |
Antimalarial treatment of rheumatoid arthritis: 1985 status.
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Drug Combinations; Gold; Humans; Hydroxychloroqui | 1985 |
Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity.
Topics: Adult; Age Factors; Chloroquine; Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Middl | 1985 |
[Influence of the level of environmental illumination on the ocular changes induced by hydroxychloroquine in the rat].
Topics: Animals; Electroretinography; Hydroxychloroquine; Light; Male; Melanins; Rats; Retinal Diseases; Tim | 1973 |
Discoid lupus erythematosus.
Topics: Adult; Antimalarials; Chloroquine; Color Vision Defects; Female; Humans; Hydroxychloroquine; Lupus E | 1972 |
[Chloroquine retinopathy].
Topics: Adult; Aged; Chloroquine; Color Vision Defects; Dark Adaptation; Electrooculography; Electroretinogr | 1972 |
Chloroquine-induced ocular toxicity.
Topics: Chloroquine; Color Perception; Cornea; Female; Humans; Hydroxychloroquine; Male; Retinal Diseases; V | 1974 |